Page last updated: 2024-12-05

tocopherols

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Tocopherols are a group of fat-soluble vitamin E compounds that act as antioxidants in the body. They protect cells from damage caused by free radicals. Alpha-tocopherol is the most biologically active form of vitamin E and is typically found in vegetable oils. Tocopherols are synthesized through a series of enzymatic reactions in plants. They play an important role in human health, protecting cells from damage caused by oxidative stress. Their antioxidant activity helps to prevent diseases like cancer, heart disease, and Alzheimer’s disease. Due to their potential health benefits, tocopherols are a subject of ongoing research to explore their therapeutic applications.'

Cross-References

ID SourceID
PubMed CID14986
CHEMBL ID420898
SCHEMBL ID39640
MeSH IDM0022803

Synonyms (50)

Synonym
1406-66-2
methyltocols
tocopherols ,
e-mix 80
ccris 4506
3,4-dihydro-2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-2h-1-benzopyran-6-ol
7616-22-0
2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydro-2h-chromen-6-ol
2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromen-6-ol
CHEMBL420898
2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)chroman-6-ol
tocopherol [jan]
ec 604-195-9
unii-r0zb2556p8
r0zb2556p8 ,
ecy0xg64do ,
3,4-dihydro-2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-2h-benzopyran-6-ol
unii-ecy0xg64do
2h-1-benzopyran-6-ol, 3,4-dihydro-2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-
einecs 231-523-4
gamma-tocopherol, dl-
ccris 3610
FT-0626624
FT-0624546
d-.gamma.-tocopherol
SCHEMBL39640
.gamma.-tocopherol, dl-
(+/-)-7,8-dimethyltocol
(+/-)-gamma-tocopherol
6-chromanol, 2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-
.gamma.-tocopherol dl-form [mi]
j34.135e ,
j816.831h
dl-.gamma.-tocopherol
(all-rac)-.gamma.-tocopherol
DTXSID5044075
.gamma.-tokoferol
7,8-dimethyltocolo-xylotocopherol
QUEDXNHFTDJVIY-UHFFFAOYSA-N
2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol #
73980-80-0
rac-gamma-tocopherol
FT-0756458
Q27277111
dl-gamma-tocopherol
( inverted exclamation marka)-|a-tocopherol
()--tocopherol
(+/-)-?-tocopherol
HY-N7148A
CS-0113315

Research Excerpts

Overview

Tocopherols are a class of molecules with vitamin E activity.

ExcerptReferenceRelevance
"Tocopherols are a class of molecules with vitamin E activity. "( Computational solvent system screening for the separation of tocopherols with centrifugal partition chromatography using deep eutectic solvent-based biphasic systems.
Bezold, F; Minceva, M; Weinberger, ME, 2017
)
2.14

Effects

ExcerptReferenceRelevance
"Tocopherols have been found in many different plant species, and plant tissues."( Differential distribution of tocopherols and tocotrienols in photosynthetic and non-photosynthetic tissues.
Bigirimana, J; Caubergs, R; Guisez, Y; Horemans, N; Horvath, G; Jansen, M; Wessjohann, L, 2006
)
1.35

Toxicity

ExcerptReferenceRelevance
"Rat hepatocyte suspensions were exposed to toxic concentrations of cadmium (Cd) in the presence and absence of unesterified alpha-tocopherol (T) or alpha-tocopheryl succinate (TS)."( Cadmium toxicity: unique cytoprotective properties of alpha tocopheryl succinate in hepatocytes.
Fariss, MW, 1991
)
0.28
"2 nmol/10(6) cells) but failed to protect these hepatocytes from the toxic effects of oxygen."( Oxygen toxicity: unique cytoprotective properties of vitamin E succinate in hepatocytes.
Fariss, MW, 1990
)
0.28
" concentration of the SH-groups, activity of glutathione reductase and glutathione-S-transferase, carminomycin antitumor and toxic effects was studied under conditions of tumor growth and carminomycin therapy with the use of prophylactic rations (PR) aimed at stimulating the cell thiol-dependent and antioxidant systems for decreasing the drug toxic action."( [Thiol-dependent protective systems in alimentary prevention of the toxic effect of carminomycin].
Alekseeva, NR; Karsybekova, NM; Lenskaia, EG; Monakhov, BV; Sarbaev, BT; Sisemalieva, ZhS; Tazhibaev, ShS, 1990
)
0.28
"Rat and canine hepatocyte suspensions were exposed to toxic concentrations of ethyl methanesulfonate (EMS) and ionophore A-23187 in the presence and absence of extracellular calcium (Ca2+) and alpha-tocopheryl succinate (alpha-TS)."( Alpha-tocopheryl succinate protects hepatocytes from chemical-induced toxicity under physiological calcium conditions.
Fariss, MW; Merson, MH; O'Hara, TM, 1989
)
0.28
"Previous studies from our laboratory have demonstrated that the administration of alpha-tocopheryl hemisuccinate (TS), but not unesterified alpha-tocopherol (T), protects hepatocytes from a variety of toxic insults including chemicals, drugs, metals, and oxidative stress."( Role of cellular energy status in tocopheryl hemisuccinate cytoprotection against ethyl methanesulfonate-induced toxicity.
Fariss, MW; Ray, SD, 1994
)
0.29
"The mechanisms by which hydrophobic bile acids are toxic to the liver are unknown."( Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes.
Devereaux, M; Khandwala, R; O'Brien, K; Sokol, RJ, 1993
)
0.29
" Pretreatment of hepatocytes with medium deficient in sulfur amino acids accelerated cell death induced by EMS, confirming the previously reported cytoprotective role for GSH in this toxic event."( Role of cellular thiol status in tocopheryl hemisuccinate cytoprotection against ethyl methanesulfonate-induced toxicity.
Bryson, KF; Fariss, MW; Tirmenstein, MA, 1997
)
0.3
" In addition to lens opacification (cataracts) and histological changes associated with pneumotoxicity, other biomarkers of toxic effects include glutathione depletion, lipid peroxidation, DNA fragmentation and the production of the active oxygen species as superoxide anion and hydroxyl radical."( Naphthalene toxicity and antioxidant nutrients.
Bagchi, D; Ohia, S; Stohs, SJ, 2002
)
0.31
" The toxic potential resulting from our data would be valproic acid < cyclosporine A < amiodarone."( Cytotoxicity evaluation after coexposure to perchloroethylene and selected peroxidant drugs in rat hepatocytes.
Barbaro, M; Catania, S; Costa, C; Germanò, MP; Silvari, V, 2004
)
0.32
" In the present study, estrogenic and toxic effects of PCBs on embryonic chicken ovarian development were evaluated by a germ-somatic cell co-culture system."( Estrogenic and toxic effects of polychlorinated biphenyls on cultured ovarian germ cells of embryonic chickens.
Xie, M; Zhang, C, 2004
)
0.32
" These data suggest that antioxidants may serve as 'Abeta targeting' therapies that suppress toxic protein aggregation rather than simply acting as downstream radical scavengers."( Role of glutathione in intracellular amyloid-alpha precursor protein/carboxy-terminal fragment aggregation and associated cytotoxicity.
Maezawa, I; Milatovic, D; Montine, KS; Montine, TJ; Nghiem, W; Vaisar, T; Woltjer, RL, 2005
)
0.33
" Since testicular function is exquisitely susceptible to reactive-oxygen species, the present study elucidates the possible involvement of oxidative stress in vanadium-induced testicular toxicity and the prophylactic effects of vitamin E acetate against such adverse effects of vanadium."( Amelioration of vanadium-induced testicular toxicity and adrenocortical hyperactivity by vitamin E acetate in rats.
Chandra, AK; Chatterjee, A; Ghosh, R; Sarkar, M, 2007
)
0.34
" VitE analogues such as alpha-TOS have been developed for clinical use as supplements mainly for the treatment of VitE deficiency and are considered safe and non-toxic when taken orally."( Alpha-Tocopheryl succinate: toxicity and lack of anti-tumour activity in immuno-competent mice.
Beilharz, MW; Ireland, DJ; Kissick, HT, 2008
)
0.35
" This drug, at effective higher doses, causes many physiological adverse effects such as nephrotoxicity and genotoxicity."( Prevention of cisplatin-induced nephrotoxicity by glucosides of ascorbic acid and alpha-tocopherol.
Kagiya, TV; Maliakel, DM; Nair, CK, 2008
)
0.35
" Adverse events were recorded."( Immunogenicity and safety of an AS03(A)-adjuvanted H5N1 influenza vaccine in a Taiwanese population.
Bock, HL; Chan, YJ; Chang, SC; Chen, TJ; Dramé, M; Hsieh, SL; Hwang, SJ; Lai, HY; Lin, MH; Liu, JY; Ong, G; Roman, F; Yang, PC; Yu, CJ, 2011
)
0.37
" In conclusion, the nanoparticles containing antioxidant actives were safe for topical use and presented anti-aging activity in vivo and are suitable to be used as cosmetic ingredient."( Safety and efficacy of antioxidants-loaded nanoparticles for an anti-aging application.
Bruschi, M; Carvalho, AR; Felippi, CC; Oliveira, D; Raffin, RP; Ströher, A; Van Etten, EA, 2012
)
0.38
" It was concluded that α-tocopherol supplementation reduced the toxic effects of SA exposure on ovarian tissue in rats."( Histological and histometrical study of the protective role of α-tocopherol against sodium arsenite toxicity in rat ovaries.
Dezfouli, MG; Eissazadeh, S; Zade, SM, 2014
)
0.4
" Preclinical in vitro and in vivo data demonstrated that α-TEA is a potent anti-tumor agent with a safe toxicity profile in mice."( GMP-grade α-TEA lysine salt: a 28-Day oral toxicity and toxicokinetic study with a 28-Day recovery period in Beagle dogs.
Akporiaye, ET; Alderman, Z; Curti, B; Guerrouahen, BS; Hahn, T; Urba, W, 2016
)
0.43
"We demonstrate that for designing clinical trials in patients, the highest non-severely toxic dose (HNSTD) of α-TEA is 1500 mg/kg/day in Beagle dogs and this data informed the design of dose-escalation studies of α-TEA in patients with advanced cancer."( GMP-grade α-TEA lysine salt: a 28-Day oral toxicity and toxicokinetic study with a 28-Day recovery period in Beagle dogs.
Akporiaye, ET; Alderman, Z; Curti, B; Guerrouahen, BS; Hahn, T; Urba, W, 2016
)
0.43
"The Cosmetic Ingredient Review (CIR) Expert Panel (Panel) assessed the safety of 14 tocopherols and tocotrienols and concluded these ingredients are safe as used in cosmetics."( Safety Assessment of Tocopherols and Tocotrienols as Used in Cosmetics.
Andersen, FA; Belsito, DV; Bergfeld, WF; Fiume, MM; Heldreth, B; Hill, RA; Klaassen, CD; Liebler, DC; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW,
)
0.67
"Cisplatin (CP) is a conventional chemotherapeutic agent with serious adverse effects."( Baicalein and Αlpha-Tocopherol Inhibit Toll-like Receptor Pathways in Cisplatin-Induced Nephrotoxicity.
Abdelbaset-Ismail, A; Awadalla, A; El-Dosoky, M; Mahdi, MR; Negm, A; Zahran, MH, 2022
)
0.72
" To prevent, or even treat, certain age-related or civilization diseases associated with increased levels of 7-ketocholesterol and 7β-hydroxycholesterol, the identification of molecules or mixtures of molecules attenuating or inhibiting the toxic effects of these oxysterols allows to consider new treatments."( Cytoprotective activities of representative nutrients from the Mediterranean diet and of Mediterranean oils against 7-ketocholesterol- and 7β-hydroxycholesterol-induced cytotoxicity: Application to age-related diseases and civilization diseases.
Chouaibi, M; Ghzaiel, I; Ksila, M; Lizard, G; Nury, T; Rezig, L; Samadi, M; Vejux, A; Yammine, A; Zarrouk, A, 2022
)
0.72
"Carfilzomib (Cfz) is an anti-cancer drug related to cardiorenal adverse events, with cardiovascular and renal complications limiting its clinical use."( An Untargeted Metabolomics Approach on Carfilzomib-Induced Nephrotoxicity.
Andreadou, I; Barla, I; Dimopoulos, MA; Efentakis, P; Gavriatopoulou, M; Gikas, E; Lamprou, S; Terpos, E; Thomaidis, N, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effect of dl-alpha-tocopheryl (vitamin E) succinate in combination with Prostaglandin A2 (PGA2) and sodium butyrate on mouse neuroblastoma cells (NBP2) in culture, according to the criteria of growth inhibition and morphological differentiation (neurite formation), was studied."( Effects of dl-alpha-tocopheryl succinate in combination with sodium butyrate and cAMP stimulating agent on neuroblastoma cells in culture.
Prasad, KN; Rama, BN, 1984
)
0.27
"The effect of heat in combination with DL-alpha-tocopheryl (vitamin E) succinate and adenosine 3', 5'-cyclic monophosphate (cAMP) stimulating agents on mouse neuroblastoma cells ( NBP2 ) in culture on the criterion of growth inhibition (due to cell death and inhibition of cell division) was studied."( Effect of hyperthermia in combination with vitamin E and cyclic AMP on neuroblastoma cells in culture.
Prasad, KN; Rama, BN, 1984
)
0.27
" N-PLS was found to be more suitable than PARAFAC combined with multiple linear regression for correlating fluorescence and quality parameters, yielding better fits and lower prediction errors."( Excitation-emission fluorescence spectroscopy combined with three-way methods of analysis as a complementary technique for olive oil characterization.
Boqué, R; Ferré, J; Garcia, J; Guimet, F; Vidal, M, 2005
)
0.33
"In this study, we evaluated the efficacy of vesiculated alpha-tocopheryl succinate (Valpha-TOS) in combination with non-antigen pulsed, nonmatured dendritic cells (nmDC) to treat pre-established tumors of the highly metastatic murine mammary cancer cell line 4T1."( Chemo-immunotherapy of breast cancer using vesiculated alpha-tocopheryl succinate in combination with dendritic cell vaccination.
Akporiaye, ET; Dial, SM; Hahn, T; Ramanathapuram, LV, 2005
)
0.33
" An analytical method based on DBS cards (FTA® DMPK-A) combined with liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) has been developed and validated for the determination of carotenoids (lutein, zeaxanthin, β-cryptoxanthin and β-carotene), tocopherols (α-tocopherol, γ-tocopherol and δ-tocopherol) and all-trans-retinol in human blood."( Application of Dried Blood Spot Cards combined with liquid chromatography-tandem mass spectrometry to determine eight fat-soluble micronutrients in human blood.
Calderón, L; Companys, J; Ludwig, I; Macià, A; Motilva, MJ; Pla-Pagà, L; Romero, MP; Rubió, L; Yuste, S, 2020
)
0.74
"To evaluate the efficacy of keishibukuryogan, a traditional Kampo formula known to be an anti-Oketsu (impaired microcirculation and non-physiological blood congestion) drug, in combination with an anti-oxidant for the treatment of varicoceles."( Effect of keishibukuryogan combined with tocopherol nicotinate on sperm parameters in patients with a varicocele.
Ishibashi, Y; Karibe, J; Komeya, M; Kuroda, S; Mori, K; Saito, T; Takeshima, T; Usui, K; Yumura, Y, 2022
)
0.72

Bioavailability

Dietary fat and energy may affect intake and bioavailability of carotenoids and tocopherols. The increasedBioavailability of tocop herols in the presence of dietary lignans might be due to the regeneration of oxidized tocop Herols, according to the study.

ExcerptReferenceRelevance
" For the TPGS, a water-soluble form of vitamin E, the indices of bioavailability were lower (P less than ."( Bioavailability of vitamin E compounds in lambs.
Antapli, M; Hidiroglou, N; McDowell, LR; Papas, AM; Wilkinson, NS, 1992
)
0.28
"Twenty-five yearling wethers, weighing 45 to 50 kg, were used in a trial designed to compare the bioavailability of dl-alpha-tocopheryl acetate (TA) and d-alpha-tocopheryl polyethylene glycol-1000 succinate (TPGS)."( Plasma alpha-tocopherol profiles in sheep after oral administration of dl-alpha-tocopheryl acetate and d-alpha-tocopheryl polyethylene glycol-1000 succinate.
Hidiroglou, M; Ivan, M, 1991
)
0.28
" The rate of absorption and elimination, as well as the lag phase, were independent of the dose, but the extent of absorption was directly proportional to dose."( Disposition kinetics and dosage regimen of vitamin E administered intramuscularly to sheep.
Hidiroglou, M; Karpinski, K, 1991
)
0.28
"The purpose of this study was to compare the bioavailability of dl-alpha-tocopheryl acetate and d-alpha-tocopheryl succinate when administered to sheep in a single oral dose weekly."( Plasma alpha-tocopherol profiles in sheep after oral administration of dl-alpha-tocopheryl acetate and d-alpha-tocopheryl succinate.
Hidiroglou, M; Singh, K, 1991
)
0.28
"An experiment was conducted to compare the bioavailability of dl-alpha-tocopherol acetate (TA) with that of dl-alpha-tocopherol nicotinate (TN) when administered to sheep, as a single dose, either into the rumen or the peritoneal cavity."( Comparative studies on bioavailability and tissue uptake of two intraruminally or intraperitoneally administered esters of alpha-tocopherol in sheep.
Charmley, E; Hidiroglou, M, 1991
)
0.28
"The bioavailability of alpha-tocopherol acetate and alpha-tocopherol (vitamin E) was assessed in male rabbits given 50 mg kg-1 doses according to a randomized design."( Bioavailability of intramuscular vitamin E acetate in rabbits.
Bonati, M; Bortolotti, A; Calvo, B; Celardo, A; Pedraz, JL, 1989
)
0.28
"Two trials were carried out to evaluate the bioavailability of dl-alpha-tocopherol and dl-alpha-tocopherol acetate administered to sheep and cattle in a single oral dose."( Plasma tocopherol in sheep and cattle after ingesting free or acetylated tocopherol.
Balbuena, O; Hidiroglou, N; McDowell, LR, 1989
)
0.28
" It was shown that there was a large difference in the relative bioavailability of the two compounds with a four times higher (P < ."( Metabolism of tritiated D-alpha-tocopherol and D-alpha-tocopheryl succinate in intraruminally dosed sheep.
Hidiroglou, M; Ivan, M; Toutain, PL, 1994
)
0.29
" The data also showed that the bioavailability of alpha-tocopherol is dependent on the form administered."( Serum total cholesterol, high-density lipoprotein-cholesterol and triglyceride concentrations in lambs following supplementation with various forms of tocopherol.
Antapli, M; Hidiroglou, N; McDowell, LR; Papas, AM; Wilkinson, NS; Wolynetz, MS, 1993
)
0.29
"Two trials were carried out to evaluate the bioavailability of 2 vitamin E components, D-alpha-tocopherol and DL-alpha-tocopherol acetate administered to 6 cattle intramuscularly (IM)."( A dynamic evaluation of the bioavailability of the free and ester forms of vitamin E administered intramuscularly to beef cattle.
Hidiroglou, N; Laflamme, LF, 1993
)
0.29
"The bioavailability of RRR-alpha-tocopherol from the oral administration of RRR-alpha-tocopherol itself and its acetate and succinate esters was determined in healthy human subjects."( Biokinetics in humans of RRR-alpha-tocopherol: the free phenol, acetate ester, and succinate ester forms of vitamin E.
Burton, G; Cheeseman, KH; Holley, AE; Hughes, L; Kelly, FJ; Wasil, M, 1995
)
0.29
"The effects of daily supplementation of 1000 IU of d-alpha- or dl-alpha-tocopherol acetate to Holstein cows from drying off to 8 wk after calving were studied 1) to compare the bioavailability of d-alpha- and dl-alpha-tocopherol acetate by monitoring vitamin E concentrations in plasma, red blood cells, and neutrophils and 2) to determine the effect of d-alpha- and dl-alpha-tocopherol acetate supplementation on O2- and H2O2 release by neutrophils."( Bioavailability of vitamin E compounds and the effect of supplementation on release of superoxide and hydrogen peroxide by bovine neutrophils.
Batra, TR; Hidiroglou, M; Zhao, X, 1997
)
0.3
" In this study we assessed the relative bioavailability of three formulations of DL-alpha-tocopheryl acetate in a kinetic study of plasma alpha-tocopherol in four Italian Friesian dairy cows, following intraruminal administration of a gelatin capsule containing 5,000 IU of DL-alpha-tocopheryl acetate."( Relative bioavailability of vitamin E in dairy cows following intraruminal administration of three different preparations of DL-alpha-tocopheryl acetate.
Baldi, A; Bontempo, V; Carli, S; Cheli, F; Dell'Orto, V; Sgoifo Rossi, C,
)
0.13
" These data suggest that vitamin E bioavailability is similar between a 15 and 35% fat diet, with a redistribution of alpha-tocopherol in lipoproteins occurring during low-fat feeding (increased in the VLDL fraction, reduced in the other lipoproteins), and transfer of alpha-tocopherol from VLDL depends upon TG removal from the particle, consistent with previous observations in vitro and in animal studies."( Dependence of plasma alpha-tocopherol flux on very low-density triglyceride clearance in humans.
Dare, D; Frazier, KB; Hellerstein, MK; Hughes, E; Neese, RA; Parks, EJ; Traber, MG, 2000
)
0.31
"The results confirm that the relative bioavailability of beta-carotene depends largely on the source of b-carotene and demonstrate the superior bioavailability of beta-carotene powder in comparison to that in carrot juice."( Plasma concentration response to drinks containing beta-carotene as carrot juice or formulated as a water dispersible powder.
Aebischer, CP; Cohn, W; Schalch, W; Steffen, J; Thürmann, PA; Wendt, G; Zwernemann, C, 2002
)
0.31
" Dietary fat and energy may affect intake and bioavailability of carotenoids and tocopherols, and these micronutrient levels in turn can contribute to the antioxidant capacity of plasma."( Plasma carotenoids, tocopherols, and antioxidant capacity in a 12-week intervention study to reduce fat and/or energy intakes.
Djuric, Z; Heilbrun, LK; Lababidi, S; Macha, S; Naegeli, L; Uhley, VE, 2003
)
0.87
" One plausible explanation is that the potential health benefits of alpha-tocopherol supplements are offset by deleterious changes in the bioavailability and/or bioactivity of other nutrients."( Supplementation of diets with alpha-tocopherol reduces serum concentrations of gamma- and delta-tocopherol in humans.
Appel, LJ; Huang, HY, 2003
)
0.32
" Several assays to measure 'total' antioxidant capacity of plasma have been developed to study the involvement of oxidative stress in pathological conditions and to evaluate the functional bioavailability of dietary antioxidants."( Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma.
Aldini, G; Krinsky, NI; Russell, RM; Yeum, KJ, 2004
)
0.32
" The increased bioavailability of tocopherols in the presence of dietary lignans might be due to the regeneration of oxidized tocopherols."( Dietary sesame oils inhibits iron-induced oxidative stress in rats [corrected].
Hemalatha, S; Raghunath, M, 2004
)
0.6
" We hypothesized that the bioavailability of vitamin E in human skin is, at least in part, dependent on sebaceous gland secretion."( Oral supplementation with all-Rac- and RRR-alpha-tocopherol increases vitamin E levels in human sebum after a latency period of 14-21 days.
Ekanayake-Mudiyanselage, S; Kraemer, K; Thiele, JJ, 2004
)
0.32
" There is also a need to clarify the bioavailability of natural and synthetic vitamin E, which is currently a subject of some controversy."( Vitamin E bioavailability in humans.
Lodge, JK, 2005
)
0.33
" These results demonstrate that the SEDDS of itraconazole composed of Transcutol, Pluronic L64 and tocopherol acetate greatly enhanced the bioavailability of itraconazole after the dose, particularly not influenced by food intake or not."( A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption.
Hong, JY; Kim, CK; Kim, JK; Park, JS; Song, YK, 2006
)
0.33
" (R,R,R)-gamma-tocopherol bioavailability was compared between wild-type mice and mice overexpressing SR-BI in the intestine."( Scavenger receptor class B type I (SR-BI) is involved in vitamin E transport across the enterocyte.
Bietrix, F; Borel, P; Collet, X; Gleize, B; Klein, A; Lagrost, L; Malezet-Desmoulins, C; Margotat, A; Reboul, E; Schneider, M, 2006
)
0.33
" Assessment of bioavailability within the body is therefore considered to be a good and easy way to predict biological value."( Bioavailability of alpha-tocopherol stereoisomers in rats depends on dietary doses of all-rac- or RRR-alpha-tocopheryl acetate.
Jensen, SK; Lauridsen, C; Nørgaard, JV, 2006
)
0.33
"We previously demonstrated that a novel hydrophilic gamma-tocopherol (gamma-Toc) derivative, gamma-tocopherol-N,N-dimethylglycinate hydrochloride (gamma-TDMG) converts to gamma-Toc in the mouse skin and has a higher bioavailability than gamma-Toc itself."( Topical application of a novel, hydrophilic gamma-tocopherol derivative reduces photo-inflammation in mice skin.
Karube, Y; Kobayashi, S; Takata, J; Watanabe, T; Yamazaki, A; Yoshida, E, 2006
)
0.33
" Bioavailability is a critical feature in the assessment of the role of micronutrients in human health, and the approaches to this issue include in vitro and in vivo methods."( Bioavailability of carotenoids and tocopherols from broccoli: in vivo and in vitro assessment.
Blanco, I; Blázquez, S; Granado, F; Herrero, C; Olmedilla, B; Pérez-Sacristán, B, 2006
)
0.61
" The goal of this study is to determine whether cellular Vit E bioavailability and its transport proteins are important contributing factors."( Differential retention of alpha-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells.
Ni, J; Pang, ST; Yeh, S, 2007
)
0.34
"Antiproliferative efficacy of alpha-Vit E is correlated with its cellular bioavailability in PCa cells."( Differential retention of alpha-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells.
Ni, J; Pang, ST; Yeh, S, 2007
)
0.34
" This study suggests that nano-sized emulsions significantly increase the bioavailability of transdermally applied delta tocopherol."( Increased bioavailability of a transdermal application of a nano-sized emulsion preparation.
Kotyla, T; Kuo, F; Moolchandani, V; Nicolosi, R; Wilson, T, 2008
)
0.35
"The present study investigated whether MicroFluidizer Processor-based nanoemulsions of an antioxidant synergy formulation (ASF), containing delta, alpha and gamma tocopherol influenced inflammation and bioavailability in CD-1 mice."( Nanoemulsions of an anti-oxidant synergy formulation containing gamma tocopherol have enhanced bioavailability and anti-inflammatory properties.
Kotyla, T; Kuo, F; Nicolosi, RJ; Subramanian, B; Wilson, TA; Yoganathan, S, 2008
)
0.35
"Bioactive constituents of pecan nuts such as γ-tocopherol and flavan-3-ol monomers show antioxidant properties in vitro, but bioavailability in humans is not known."( Pecans acutely increase plasma postprandial antioxidant capacity and catechins and decrease LDL oxidation in humans.
Haddad, EH; Hudthagosol, C; McCarthy, K; Oda, K; Sabaté, J; Wang, P, 2011
)
0.37
" A single-dose bioavailability study was completed on day 1 and isoflavones in plasma and urine, and lycopene in the plasma, were measured."( Bioavailability of phytochemical constituents from a novel soy fortified lycopene rich tomato juice developed for targeted cancer prevention trials.
Blackwood, M; Bohn, T; Clinton, SK; Francis, D; Schwartz, SJ; Tian, Q, 2013
)
0.39
" Low-phytate (LP) grain is distinguished by containing not only a reduced level of phytate P but also an increased level of inorganic P, resulting in greater bioavailability of P and mineral cations in animal diets."( Compositional equivalence of barleys differing only in low- and normal-phytate levels.
Bregitzer, P; Hicks, KB; Liu, K; Moreau, RA, 2012
)
0.38
" The bioavailability of the many antioxidant ingredients a vitamin and trace element composition was investigated, to reveal the neuroprotective (preventive) potential of the composition."( Neuroprotective impact of a vitamin trace element composition - a randomized, double blind, placebo controlled clinical trial with healthy volunteers.
Endler, T; Mosgoeller, W; Muss, C, 2015
)
0.42
" We confirmed the bioavailability of ingredients, and determined metabolic parameters associated with the integrity of the blood brain barrier, mitochondrial deficiency (Q 10), neurodegeneration (homocystein), and antioxidative capacity (e."( Neuroprotective impact of a vitamin trace element composition - a randomized, double blind, placebo controlled clinical trial with healthy volunteers.
Endler, T; Mosgoeller, W; Muss, C, 2015
)
0.42
" Taking into account the bioavailability of these compounds, it is evident that a number of factors affect the antioxidant composition of rice, making it difficult to estimate dietary intake."( Factors influencing antioxidant compounds in rice.
Goufo, P; Trindade, H, 2017
)
0.46
"New sources of dioxins and increased dioxin concentrations in the environment, coupled with their increased bioavailability along the food chain and accumulation in adipose tissues, contribute to various adverse long-term biological effects."( Effect of tocopherol and acetylsalicylic acid on the biochemical indices of blood in dioxin-exposed rats.
Całkosiński, I; Rosińczuk, J, 2015
)
0.42
"Further studies are necessary to deepen knowledge on this area, namely focusing on in vivo experiments, to establish upcoming guidelines to improve the quality and bioavailability of phytopharmacologic formulations."( Phytopharmacologic preparations as predictors of plant bioactivity: A particular approach to Echinacea purpurea (L.) Moench antioxidant properties.
Barros, L; Carvalho, AM; Ferreira, IC; Martins, N; Pires, C,
)
0.13
" Compared to tocopherols, less research has been conducted on these compounds because of their low bioavailability and distribution in plant tissues."( Advances in Genetic Improvement for Tocotrienol Production: A Review.
Abdullah, SNA; Babura, SR; Khaza Ai, H, 2017
)
0.82
" Their ability to solubilise poorly water soluble drugs indicates their potential utility in improving bioavailability of drugs where solubility limits their bioavailability."( A new lipid excipient, phosphorylated tocopherol mixture, TPM enhances the solubilisation and oral bioavailability of poorly water soluble CoQ
Boyd, BJ; Gavin, P; Libinaki, R; Pham, AC; Ramirez, G, 2017
)
0.46
" Thus, SIRT1 may regulate vitamin E transportation and bioavailability at cellular level."( Cellular Uptake and Bioavailability of Tocotrienol-Rich Fraction in SIRT1-Inhibited Human Diploid Fibroblasts.
Abdullah, A; Jaafar, F; Makpol, S, 2018
)
0.48
" The increased bioavailability of VE by antibiotics is probably due to increased absorption of VE or its decreased degradation by gut microbes."( Effects of antibiotics on degradation and bioavailability of different vitamin E forms in mice.
Lee, MJ; Lin, Y; Liu, AB; Ran, L; Xie, P; Yang, CS, 2019
)
0.51
" However, the bioavailability of these metabolites has not been well characterized."( Tocopherols and Tocotrienols Are Bioavailable in Rats and Primarily Excreted in Feces as the Intact Forms and 13'-Carboxychromanol Metabolites.
Jiang, Q; Liu, KY, 2020
)
2
" In comparison with α-T, these forms have much lower systemic bioavailability but have shown stronger cancer-preventive activities in many studies in animal models and cell lines."( Vitamin E and cancer prevention: Studies with different forms of tocopherols and tocotrienols.
Luo, P; Malafa, M; Suh, N; Wang, H; Yang, CS; Zeng, Z, 2020
)
0.8
" To explain the lower lycopene and α-carotene concentration in older subjects, bioavailability studies in older participants are necessary."( Plasma carotenoids, tocopherols and retinol - Association with age in the Berlin Aging Study II.
Demuth, I; Grune, T; Kochlik, B; Norman, K; Steinhagen-Thiessen, E; Weber, D, 2020
)
0.88

Dosage Studied

ExcerptRelevanceReference
" Plasma samples were taken at regular intervals after dosing and assayed for radioactivity and D-alpha-tocopherol."( Vitamin E kinetics after intraperitoneal administration of DL-alpha-tocopherol and DL-alpha-tocopherol acetate in sheep.
Hidiroglou, M; Hidiroglou, N; Laurentie, MP; Toutain, PL, 1992
)
0.28
"01) plasma alpha-tocopherol concentrations during the three-week experimental period in sheep dosed with equivalent units of TA than in those dosed with TPGS."( Plasma alpha-tocopherol profiles in sheep after oral administration of dl-alpha-tocopheryl acetate and d-alpha-tocopheryl polyethylene glycol-1000 succinate.
Hidiroglou, M; Ivan, M, 1991
)
0.28
" The mean hepatic alpha-tocopherol concentrations in both groups rose rapidly and after 4 weeks of dosing its concentrations were higher than the predosing levels."( Disposition kinetics and dosage regimen of vitamin E administered intramuscularly to sheep.
Hidiroglou, M; Karpinski, K, 1991
)
0.28
" Of these, 10 wethers were killed three days after dosing (five from each treatment, IR3 and IP3) and the remaining wethers were killed eight days after dosing (IR8 and IP8)."( Vitamin E concentrations in blood plasma of sheep and in sheep tissues after a single intraruminal or intraperitoneal administration of DL-alpha-tocopheryl acetate.
Charmley, E; Hidiroglou, M, 1990
)
0.28
" Administration of 1 g caused a small increase in blood and milk concentrations; dosing with 5 g IP caused appreciable increases in both plasma and milk concentrations."( Effect of intraperitoneally injected tocopherol on vitamin E status of dairy cow.
Atwal, AS; Hidiroglou, M, 1989
)
0.28
" These data suggest that if a policy of VE supplementation for VLBW infants is chosen, monitoring of plasma VE levels appears necessary so that the dosage can be adjusted in order to maintain plasma VE within the optimal range."( Distribution of plasma vitamin E levels in supplemented very low birthweight infants.
Arnold, JD; Earl, JW; Leslie, GI; O'Halloran, M, 1989
)
0.28
" The emergence of a toxic clinical syndrome associated with vitamin E therapy, the effects of vitamin E on important physiologic systems such as granulocyte function and the arachidonic acid cascade, the theoretic possibility of vitamin E becoming a prooxidant at high concentrations, and the continuing controversy regarding the efficacy of pharmacologic doses of vitamin E mandate further study of the dose-response nature of pharmacologic vitamin E therapy from both an efficacy and toxicity perspective."( Pharmacology of vitamin E in the newborn.
Knight, ME; Roberts, RJ, 1987
)
0.27
" The results showed that biological availability was higher after D-alpha-tocopherol dosing than after the other forms."( Pharmacokinetic disposition in sheep of various vitamin E preparations given orally or intravenously.
Hidiroglou, M; Karpinski, K, 1988
)
0.27
" The variable pattern in tocopherol concentrations in the various sheep tissues following vitamin E dosing was considered a reflection of their different metabolic activities."( Vitamin E levels in sheep tissues at various times after a single oral administration of d-alpha-tocopherol acetate.
Hidiroglou, M, 1987
)
0.27
" The animals were killed 5 min after dosing to minimize the conversion of alpha-tocopheryl acetate to alpha-tocopherol."( Comparison of the antioxidant properties of alpha-tocopherol and alpha-tocopheryl acetate in newborn rabbit lung.
Cook, J; Knight, M; Roberts, RJ; Wispe, J, 1987
)
0.27
" With vitamin E as adjunct therapy, the dosage level of penicillamine could be lowered by 50%, thereby minimizing side effects."( Interactions of vitamin E and penicillamine in the treatment of hereditary avian muscular dystrophy.
Brandon, S; Dement, SH; Hill, EJ; Park, CR; Park, JH; Serafin, WE, 1987
)
0.27
" A dose-response relationship was found; cases occurred in infants receiving E-Ferol dosages of greater than 20 U/kg/d."( Illness with fatalities in premature infants: association with an intravenous vitamin E preparation, E-Ferol.
Frank, DJ; Gaynes, RP; Kosmetatos, N; Lorch, V; Martone, WJ; Mortensen, ML; Murphy, MD; Sinha, SN; White, JW; Williams, WW, 1986
)
0.27
" Tissues were analyzed at 1, 3, and 6 days after daily dosing was begun."( Tissue vitamin E levels in newborn rabbits after pharmacologic dosing. Influence of dose, dosage form, and route of administration.
Knight, ME; Roberts, RJ, 1985
)
0.27
" Both NNT and EDP did not affect blood pressure in normotensive animals but significantly reduced blood pressure in SHR and DOCA/salt hypertensive animals in the acute studies with single dosing of 1 to 10 mg/kg (p."( Antihypertensive actions of isoprenoids.
Igarashi, T; Mori, N; Nakajima, Y; Saeki, T, 1982
)
0.26
" Over the dosage range from 0 to 20 ppm, response in tocopherol content of most tissues including platelets and red blood cells were linear."( Comparative sensitivities of tocopherol levels of platelets, red blood cells and plasma for estimating vitamin E nutritional status in the rat.
Lehmann, J, 1981
)
0.26
" Tissue changes correlated with dosage and duration of vitamin E administration and suggested massive accumulation of vitamin E in cells of the mononuclear phagocyte system."( Vitamin E toxicity in neonatal piglets.
Habersang, RW; Hale, TW; Harkey, C; Montgomery, DL; Rais-Bahrami, K, 1995
)
0.29
" Radioactivity in lymph was measured in four additional wethers dosed intraruminally (100 microCi) with the same tritiated compounds."( Metabolism of tritiated D-alpha-tocopherol and D-alpha-tocopheryl succinate in intraruminally dosed sheep.
Hidiroglou, M; Ivan, M; Toutain, PL, 1994
)
0.29
" Bioefficiencies were calculated by comparison of the dose-response curves."( Bioefficiency of different tocopherols in chicken as assessed by haemolysis test and microsomal pentane production.
Balthazary, ST; Fuhrmann, H; Sallmann, HP, 1994
)
0.59
" Groups sc(SeM+E) and imSeM+orE were stressed by dosing with protected polyunsaturated fatty acids from day 56 onwards."( Effectiveness of alpha-tocopherol and selenium supplements in preventing lupinosis-associated myopathy in sheep.
Allen, JG; Smith, GM, 1997
)
0.3
" Differences in natural and synthetic vitamin E concentrations were measured directly under equal dosage conditions using an equimolar mixture of deuterated RRR-alpha-tocopheryl acetate and all-rac-alpha-tocopheryl acetate."( Human plasma and tissue alpha-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E.
Acuff, RV; Burton, GW; Hughes, L; Ingold, KU; Kayden, H; Traber, MG; Walters, DN, 1998
)
0.3
" Data suggest that supplemental alpha-TA may be needed to counteract SSCS-induced oxidative stress, but that potential side effects introduced by high dosage of this synthetic compound should be considered."( Immunomodulatory effects of high-dose alpha-tocopherol acetate on mice subjected to sidestream cigarette smoke.
Sun, NN; Wang, S; Watson, RR; Witten, ML; Zhang, J, 2002
)
0.31
"It was the aim of the study to compare beta-carotene plasma response to b-carotene dosing with two commercially available drinks, containing beta-carotene from carrot juice or as water dispersible beta-carotene powder."( Plasma concentration response to drinks containing beta-carotene as carrot juice or formulated as a water dispersible powder.
Aebischer, CP; Cohn, W; Schalch, W; Steffen, J; Thürmann, PA; Wendt, G; Zwernemann, C, 2002
)
0.31
"Circulating concentrations of alpha-carotene, beta-carotene, and beta-cryptoxanthin inversely predicted the serum GGT concentration measured 10 years later in a dose-response manner (P for trend <0."( Association of serum carotenoids and tocopherols with gamma-glutamyltransferase: the Cardiovascular Risk Development in Young Adults (CARDIA) Study.
Gross, MD; Jacobs, DR; Lee, DH, 2004
)
0.6
" A poorer response to levodopa was associated with increased mortality independent of disease severity or dosage of levodopa."( Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.
Lang, AE; Marras, C; McDermott, MP; Naglie, G; Rochon, PA; Rudolph, A; Tanner, CM, 2005
)
0.33
" However, a randomized, double-blind, placebo-controlled, multicenter trial showed that thioctic acid at an oral dosage of 800 mg/day for 4 months significantly improved cardiac autonomic neuropathy in type 2 diabetic patients."( The role of antioxidant micronutrients in the prevention of diabetic complications.
Bonnefont-Rousselot, D, 2004
)
0.32
"An in vitro dose-response curve of human A549 lung cancer tumors to VES was established."( Vitamin E succinate decreases lung cancer tumor growth in mice.
Boley, T; Engle, D; Grasch, A; Hazelrigg, S; Litwiller, A; Peralta, E; Quin, J, 2005
)
0.33
" Thus, this system may provide a useful dosage form for oral water-insoluble drug without food effect."( A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption.
Hong, JY; Kim, CK; Kim, JK; Park, JS; Song, YK, 2006
)
0.33
"The study aimed to assess the efficacy of vitamin E-fortified apples as a low-fat vitamin E delivery system, the influence of fat on vitamin E absorption, and human vitamin E requirements by using plasma alpha-tocopherol kinetics at a dosage of alpha-tocopherol found in food."( Human vitamin E requirements assessed with the use of apples fortified with deuterium-labeled alpha-tocopheryl acetate.
Bruno, RS; Leonard, SW; Park, SI; Traber, MG; Zhao, Y, 2006
)
0.33
" A therapeutical scheme (omeprazole, metronidazole, amoxicilline) obtained a further pathogenetic substantiation of B type CG patient treatment with additional antioxidant vitamin E use at the dosage of 300 mg/day for three weeks."( [Lipid peroxidation and antioxidant system in treatment dynamics of patients with chronic gastritis].
Postavnyĭ, VE, 2005
)
0.33
"The objectives of the present research investigations were to (i) elucidate the mechanism for the oxidative degradation of Delta(9)-tetrahydrocannabinol (THC) in polymer matrix systems prepared by a hot-melt fabrication procedure, and (ii) study the potential for controlling these mechanisms to reduce the degradation of THC in solid dosage formulations."( Polymeric systems for amorphous Delta9-tetrahydrocannabinol produced by a hot-melt method. Part II: Effect of oxidation mechanisms and chemical interactions on stability.
Elsohly, MA; Munjal, M; Repka, MA, 2006
)
0.33
" Tocopherols and saponins extracted from argan tree and 2-methoxyestradiol exhibit a dose-response cytotoxic effect and an antiproliferative action on the tested cell lines."( Tocopherols and saponins derived from Argania spinosa exert, an antiproliferative effect on human prostate cancer.
Adlouni, A; Bennani, H; Charrouf, Z; Drissi, A; Fiet, J; Giton, F, 2006
)
2.69
" In the latter seven cases, vasoconstriction of the proximal MCA in response to the pressure test was eliminated by increasing the vitamin E dosage to 100 mg/day."( Effects of vitamin E on the response of the fetal middle cerebral artery to the pressure test.
Cajal, Y; Martínez, RO; Ramón, CL, 2007
)
0.34
" Surprisingly, the uptake of Tac was found to be similar to that of Tol, and in both cases, the dose-response plots suggest that protein-mediated transport processes were involved."( Alpha-tocopheryl acetate is absorbed and hydrolyzed by Caco-2 cells comparative studies with alpha-tocopherol.
Ajandouz, el H; Brisson, L; Castan, S; Fontbonne, H; Nicoletti, C; Puigserver, A, 2008
)
0.35
" Hemoglobin (Hb) levels and recombinant human erythropoietin (rHuEpo) dosage were analyzed after 4, 8, and 12 months on the VECM and compared with baseline values using paired tests."( Effect of vitamin E-coated dialysis membranes on anemia in patients with chronic kidney disease: an Italian multicenter study.
Brendolan, A; Corradi, V; Cruz, DN; De Cal, M; Garzotto, F; Nalesso, D; Ronco, C, 2008
)
0.35
" Conversely, the rHuEpo dosage decreased from 7,762 +/- 5,865 IU/week at baseline to 6,390 +/- 5,679 IU/week after 12 months (p<0."( Effect of vitamin E-coated dialysis membranes on anemia in patients with chronic kidney disease: an Italian multicenter study.
Brendolan, A; Corradi, V; Cruz, DN; De Cal, M; Garzotto, F; Nalesso, D; Ronco, C, 2008
)
0.35
" A dose-response relationship was observed for retinol (p = ."( Serum levels of retinol and other antioxidants for hearing impairment among Japanese older adults.
Asakura, K; Hosoda, K; Iwasawa, S; Kikuchi, Y; Michikawa, T; Milojevic, A; Mizutari, K; Nakano, M; Nishiwaki, Y; Saito, H; Takebayashi, T, 2009
)
0.35
"Administration of the combination of zinc-L-carnosine and vitamin E at 1X or 2X dosing did not attenuate aspirin-induced gastroduodenal mucosal injury."( Effects of zinc-L-carnosine and vitamin E on aspirin-induced gastroduodenal injury in dogs.
Baan, M; Johnson, SE; Sherding, RG,
)
0.13
" The purpose of this study was to assess its safety and pharmacokinetics after repeat dosing in a preclinical murine model."( Repeat dose study of the novel proapoptotic chemotherapeutic agent alpha-tocopheryloxy acetic acid in mice.
Akporiaye, ET; Hahn, T, 2012
)
0.38
" Feed nutrients resulted in a dose-response relationship of these compounds in the egg yolk."( Supplementation of laying-hen feed with palm tocos and algae astaxanthin for egg yolk nutrient enrichment.
Dolde, D; Walker, LA; Wang, T; Xin, H, 2012
)
0.38
" Simulations of equivalent dosing schemes ranked neutropenia severity (highest to lowest): T-pac~Cre-pac>L-pac~A-pac and predicted remarkably well the clinically-observed relationships between neutropenia and free drug exposure relative to a threshold concentration."( Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia.
Ait-Oudhia, S; Mager, DE; Straubinger, RM, 2012
)
0.38
" However, their pharmacokinetic (PK) properties remain poorly characterized, and high dosage animal studies may provide further information on their in vivo functions and pharmacological effects."( Plasma and tissue concentrations of α-tocopherol and δ-tocopherol following high dose dietary supplementation in mice.
Baxter, LL; Incao, A; Marugan, JJ; McKew, JC; Pavan, WJ; Xiao, J; Zheng, W, 2012
)
0.38
" Blood samples were taken for measurement of serum tocopherol levels by high-performance liquid chromatography before dosing and 24 hours and 7 days after dosing."( Serum tocopherol levels in very preterm infants after a single dose of vitamin E at birth.
Acarregui, MJ; Bell, EF; Brion, LP; Carlo, WA; Carlton, DP; Crawford, MM; Das, A; Ehrenkranz, RA; Ellsbury, DL; Faix, RG; Goldberg, RN; Hale, EC; Hansen, NI; Higgins, RD; Johnson, KJ; Kennedy, KA; Laptook, AR; Messina, LA; Poindexter, BB; Shankaran, S; Van Meurs, KP; Walsh, MC; Watterberg, KL, 2013
)
0.39
" The dose-response relationship was assessed by a restricted cubic spline model."( Vitamin E and risk of age-related cataract: a meta-analysis.
Jiang, W; Wu, W; Xie, Z; Zhang, D; Zhang, Y, 2015
)
0.42
" The findings from dose-response analysis showed evidence of a non-linear association between dietary vitamin E intake and ARC."( Vitamin E and risk of age-related cataract: a meta-analysis.
Jiang, W; Wu, W; Xie, Z; Zhang, D; Zhang, Y, 2015
)
0.42
" The cellular uptake of α-T3 was higher than α-TP at the same treatment dosage after 24h."( Comparative hepatoprotective effects of tocotrienol analogs against drug-induced liver injury.
Fong, CW; Ho, HK; Saw, TY; Tan, CY, 2015
)
0.42
" In the experiment, the following substances were used: 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), dosed at 5 μg/kg BW and 12."( Effect of tocopherol and acetylsalicylic acid on the biochemical indices of blood in dioxin-exposed rats.
Całkosiński, I; Rosińczuk, J, 2015
)
0.42
" In conclusion, the concentrations of vitamin E congeners and the expression of genes related to vitamin E status follow characteristic time-related changes during the transition from late gestation to early lactation but are unaffected by CLA supplementation at the dosage used."( Tocopherols and tocotrienols in serum and liver of dairy cows receiving conjugated linoleic acids or a control fat supplement during early lactation.
Dänicke, S; Frank, J; Meyer, U; Rehage, J; Sadri, H; Sauerwein, H, 2015
)
1.86
" At the end of the dosing period, blood was taken and toxicokinetic analyses and histopathology assessments were performed when animals were necropsied."( GMP-grade α-TEA lysine salt: a 28-Day oral toxicity and toxicokinetic study with a 28-Day recovery period in Beagle dogs.
Akporiaye, ET; Alderman, Z; Curti, B; Guerrouahen, BS; Hahn, T; Urba, W, 2016
)
0.43
" The present trial compares the antioxidant effectiveness following postprandial challenge of two different doses of α-T or palm T3-rich fraction (TRF) treatments and evaluates their dose-response effects on antioxidant status."( Antioxidant status following postprandial challenge of two different doses of tocopherols and tocotrienols.
Cheng, HM; Fairus, S; Sundram, K, 2020
)
0.79
" However, a significant dose-response effect was observed for plasma MDA throughout the 8-hour postprandial period."( Antioxidant status following postprandial challenge of two different doses of tocopherols and tocotrienols.
Cheng, HM; Fairus, S; Sundram, K, 2020
)
0.79
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (638 Product(s))

Product Categories

Product CategoryProducts
Compléments alimentaires, Compléments pour le Bodybuilding1
Other335
Productos no alimenticios, Open Beauty Facts1
Snacks, Snacks sucrés, Confiseries, Confiseries aux fruits1
Plant-based foods and beverages, Beverages, Dairy substitutes, Milk substitutes, Plant-based beverages, Plant-based milk alternatives1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Fruits à coques et dérivés, Fruits à coques, Fruits à coques décortiqués, Amandes, Amandes décortiquées1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Fruits à coques et dérivés, Fruits à coques, Amandes, Amandes grillées1
Viandes et dérivés, Viandes, Porc et dérivés, Porc, Palette à la diable1
Plant-based foods and beverages, Plant-based foods, Fruits and vegetables based foods, Fruits based foods, Fruits, Citrus1
Plats préparés, Salades composées1
Colazioni, Spalmabili, Spalmabili dolci, Prodotti delle api, Prodotti agricoli, Edulcoranti, Miele1
Canned foods, Meals, Soups, Canned meals, Canned soups1
Snacks, Sweet snacks, Biscuits and cakes, Biscuits2
Plant-based foods and beverages, Plant-based foods, Fruits and vegetables based foods2
Additifs alimentaires, Colorants alimentaires1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Desserts, Fruits et produits dérivés, Compotes, Compotes de pomme, Compotes pommes pruneau1
en:corn-flakes1
Viandes et dérivés, Plats préparés, Plats préparés à la viande, Plats à base de semoule, Plats au bœuf, Plats à la volaille, Couscous préparés, Plats au poulet1
Boissons, Boissons alcoolisées, Liqueurs, Crèmes de cassis2
Viandes et dérivés, Viandes, Volailles, Pintades, Cuisse de pintade1
Viandes et dérivés, Viandes, Poulet et dérivés, Volailles, Poulets, Cuisses de poulet3
Meats and their products, Meats, Prepared meats, Cured sausages, Salami1
Produits laitiers, Produits fermentés, Produits laitiers fermentés, Fromages, Fromages de vache, en:cooked-pressed-cheeses, Emmentals, Fromages de France, Emmentals français, Emmentals de Savoie2
Viandes et dérivés, Viande de bœuf et dérivés, Viandes, Bœuf, Entrecôte de boeuf2
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Céréales et pommes de terre, Céréales et dérivés, Farines, Farines de céréales, Farines de blé1
Viandes et dérivés, Viandes, Poulet et dérivés, Volailles, Poulets, Filets de poulet4
Produits de la mer, Poissons et dérivés, Poissons, Poissons gras, Anchois, Filets de poissons, Filets d'anchois, Filets d'anchois marinés, Filets d'anchois marinés à l'huile végétale1
Plant-based foods and beverages, Plant-based foods, Canned foods, Fruits and vegetables based foods, Canned plant-based foods, Vegetables based foods, Canned vegetables1
Dairies, Fermented foods, Fermented milk products, Cheeses2
Snacks, Snacks sucrés, Popcorn1
Viandes et dérivés, Viandes, Volailles, Dinde et dérivés, Dindes, Escalopes de dinde2
Seafood, Frozen foods, Frozen seafood3
Snacks, Desserts, Snacks sucrés, Biscuits et gâteaux, Pâtisseries, Macarons1
Boissons, Boissons alcoolisées, Vins, Vins français1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Snacks, Snacks salés, Fruits à coques et dérivés, Fruits à coques, Fruits à coque salés1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Fruits et produits dérivés, Produits déshydratés, Aliments à base de plantes séchées, Fruits secs, Mélanges de fruits secs1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Pickles, Produits de l'olivier, Pickles d'origine végétale, Olives, Olives dénoyautées1
Viandes et dérivés, Viandes, Charcuteries, Saucisses, Saucisses de volaille1
Produits laitiers, Produits fermentés, Produits laitiers fermentés, Fromages, Fromages de vache, Fromages de France, Fromages à pâte pressée non cuite, Morbiers1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Fruits à coques et dérivés, Fruits à coques, Noix de cajou1
Snacks3
Alimentos y bebidas de origen vegetal, Alimentos de origen vegetal, Cereales y patatas, Panes, Panes de molde1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Céréales et pommes de terre, Produits de boulangerie, Pâtes à pizza1
Viandes et dérivés, Viandes, Charcuteries, Porc et dérivés, Charcuteries diverses, Pâté, Porc, Pâtés de porc, Pâtés de campagne1
Produkty na bazie mięsa, Mięsa, Mięsa przetworzone, Szynka1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Fruits à coques et dérivés, Fruits à coques, Pistaches, Pistaches grillées1
Plats préparés, Pizzas tartes salées et quiches, Pizzas1
Viandes et dérivés, Viandes, Poulet et dérivés, Volailles, Poulets2
Aliments et boissons à base de végétaux, Boissons, Boissons à base de végétaux, Boissons aux fruits, Jus et nectars, Jus de fruits, Jus de clémentine1
Plant-based foods and beverages, Beverages, Plant-based beverages, Juices and nectars, en:fruit-juices1
Beverages, Waters, Spring waters1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Céréales et pommes de terre, Graines, Céréales et dérivés, Céréales en grains, Riz1
Sweeteners, Sugars1
Édulcorants, Sirops, Sirops simples, Sirops d'agave1
Boissons, Sirops, Sirops aromatisés, Sirops de menthe1
Snacks, Snacks sucrés, Biscuits et gâteaux, Biscuits, Tartes sucrées, Tartes, Tartelettes, Tartelettes aux fruits entiers ou coupés, Tartelettes au citron, Tartelettes à la préparation de fruits1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Fruits et produits dérivés, Produits déshydratés, Aliments à base de plantes séchées, Fruits secs1
Desserts, Frozen foods, Frozen desserts, Ice creams and sorbets, Ice creams, en:sorbets1
en:dairy-desserts1
de:Molk.S&Z MilchSauerm, en:goat-milks1
de:Müsli-&Getr.Riegel, en:bars1
en:biscuits1
Aliments et boissons à base de végétaux,Aliments d'origine végétale,Aliments à base de fruits et de légumes,Légumes et dérivés,Légumes,Légumes-feuilles,Choux cabus,Chou frisé1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Conserves, Aliments à base de fruits et de légumes, Aliments à base de plantes en conserve, Légumes et dérivés, Légumes en conserve, Légumes tiges, Asperges, Asperges blanches, Asperges1
Aliments et boissons à base de végétaux, Boissons, Aliments d'origine végétale, Boissons chaudes, Cafés, Dosettes, Cafés en dosettes1
Aliments et boissons à base de végétaux, Boissons, Aliments d'origine végétale, Boissons chaudes, Cafés, Dosettes, Cafés en dosettes, Cafés en dosettes compatible Nespresso1
Aliments et boissons à base de végétaux, Boissons, Boissons à base de végétaux, Boissons aux fruits, Boissons avec sucre ajouté1
Aliments et boissons à base de végétaux, Aliments d'origine végétale1
Alimentos y bebidas de origen vegetal, Bebidas, Bebidas de origen vegetal, Bebidas a base de frutas, Bebidas azucaradas1
Przekąski, Słodkie przekąski, en:Biscuits and cakes, Herbatnik1
en:Snacks, en:Sweet snacks, en:Confectioneries, en:Candies1
Boissons1
Desserts, Frozen foods, Frozen desserts, Ice creams and sorbets, Ice creams, Luxury ice cream in a cup, en:ice-cream-tubs1
White breads1
Botanas, Snacks dulces, Galletas y pasteles, Pasteles, Magdalenas, Mantecadas1
Plant-based foods and beverages, Plant-based foods, Cereals and potatoes, Breads, Special breads, Hot dog buns, en:pastries1
PAN DULCE RELLENO DE CHOCOLATE1
Alimentos y bebidas de origen vegetal, Alimentos de origen vegetal, Cereales y patatas, Panes, Panes integrales1
Plats préparés, Plats à base de pâtes, Pâtes farcies, Tortelloni1
Dried-soybeans,sojaböna1
Aliments pour bébé, Dès 12 mois, Dès 4 mois, Plats principaux pour bébé, Plats du soir pour bébé, Potages pour bébé1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Légumineuses et dérivés, Conserves, Aliments à base de fruits et de légumes, Légumineuses, Aliments à base de plantes en conserve, Légumes et dérivés, Légumineuses en conserve, Petits p1
Plantaardige levensmiddelen en dranken, Plantaardige levensmiddelen, Granen en aardappels, Broden, Speciale broden, Burgerbroodjes1
Snacks, Snacks sucrés, Viennoiseries, Brioches, Gâches, Brioches pur beurre, Brioches à la crème fraîche1
Snacks, Sweet snacks, Cocoa and its products, Confectioneries, Chocolates, Milk chocolates, Filled chocolates, Chocolate Block1
Snacks, Sweet snacks, Cocoa and its products, Chocolates, Dark chocolates1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Céréales et pommes de terre, Sandwichs, Pains, Pains spéciaux, Canapés, Sandwich club1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Conserves, Légumes et dérivés, Aliments à base de plantes en conserve, Légumes, Légumes en conserve, Légumes tiges, Asperges, Asperges blanches,1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Légumes et dérivés, Surgelés, Légumes, Aliments à base de plantes surgelés, Légumes surgelés, Légumes-feuilles, Épinards, Épinards surgelés1
Viandes, Volailles, Poulets, Filets de poulet1
Produits de la mer, Conserves, Mollusques, Moules, Moules en conserve1
Viandes, Charcuteries, Charcuteries cuites, Pâté en croûte1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Céréales et pommes de terre, Pains, Pains grillés, Petits pains grillés3
Viandes, Charcuteries, en:meat-based-products, Terrines, Terrines de lapin1
Viandes et dérivés,Viandes,Poulet et dérivés,Volailles,Poulets,Ailes de poulet1
Boissons, Sirops, Sirops aromatisés, Sirops de grenadine1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Céréales et pommes de terre, Pains, Biscottes1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Fruits et produits dérivés, Produits déshydratés, Fruits, Aliments à base de plantes séchées, Fruits tropicaux, Fruits secs, Noix de coco, Noix 1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Céréales et pommes de terre, Pains, Pains de mie1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Condiments, Plantes condimentaires, Plantes aromatiques, Herbes aromatiques, Estragon, en:groceries1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Condiments, Plantes condimentaires, Plantes aromatiques, en:aromatic-herbs, Persil, Plantes en pot, Plantes aromatiques en pot, Persil en pot, en:groceries1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Condiments, Epices, Mélanges d'épices, Quatre épices, en:Groceries1
Meats and their products, Meats1
Getränke, Kohlensäurehaltige Getränke, Erfrischungsgetränke, Cola, Gezuckerte Getränke1
Beverages, Carbonated drinks, en:sweetened-beverages1
en:dried-cranberries1
Petit-déjeuners, Produits à tartiner, Produits à tartiner sucrés, Produits de la ruche, Produits d'élevages, Édulcorants, Miels, Miels de manuka1
Condiments, Sels, Sels de l'Himalaya, Sels roses de l'Himalaya1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Fruits et produits dérivés, Produits déshydratés, Aliments à base de plantes séchées, Fruits secs, Baies de goji séchées1
Plats préparés, Pizzas tartes salées et quiches, Pizzas, Pizzas végétariennes, Pizza champignons fromage1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Snacks, Snacks sucrés, Confiseries, Fruits à coques et dérivés, Confiseries de fruits à coques, Cacahuètes caramélisées1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Fruits à coques et dérivés, Fruits à coques, Noix de cajou, Apéritif, Apéro1
Plant-based foods and beverages, Plant-based foods, Canned foods, Fruits and vegetables based foods, Canned plant-based foods, Fruits based foods, Canned fruits1
Alternatives à la viande, Substituts de viande, Saucisses végétariennes, en:vegan-saucages1
Desserts, Puddings2
Productos del mar, en:Fishes and their products, Pescados, en:Fatty fishes, Salmóns, Pescado ahumado, Salmones ahumados1
Viandes et dérivés, Plats préparés, Plats préparés à la viande, Plats à la volaille, Plats au poulet, Plats préparés à réchauffer au micro-ondes1
Fokproducten, Vogeleieren, Kippeneieren1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Céréales et pommes de terre, Pains, Boulangerie1
Snacks, Snacks sucrés, Biscuits et gâteaux, Gâteaux, Gâteaux au chocolat, en:chocolate-cake-with-melting-centre1
Pflanzliche Lebensmittel und Getränke, Pflanzliche Lebensmittel, Getreide und Kartoffeln, Brote, Spezielle Brote, Roggenbrote, Vollkornbrote1
Landwirtschaftliche Produkte, Vogeleier, Hühnereier, Eier aus Freilandhaltung1
Milchprodukte, Fermentierte Lebensmittel, Desserts, Fermentierte Milch, Milchnachspeisen, en:Fermented dairy desserts, Joghurt1
Tiefkühlprodukte, Fertiggerichte, Pizzas - Kuchen und Quiches, Pizzen, Gefrorene Pizzas und Quiches, Tiefkühlpizza1
Productos a base de carne, Carnes, Embutidos, Embutidos curados, Chorizo1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Snacks, Snacks sucrés, Barres, Barres de céréales1
Kasvipohjaiset ruoat ja juomat, Juomat, Kasvipohjaiset ruoat, Jyvät ja perunat, en:Dairy substitutes, Viljat ja viljatuotteet, Maidon korvike, Kasvipohjaiset juomat, Kasvipohjaiset maidonkorvikkeet, Kasvimaidot, Kaurajuomat1
9p1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Céréales et pommes de terre, Céréales et dérivés, Pâtes alimentaires, Pâtes alimentaires de céréales, Pâtes sèches, Pâtes de blé dur, Nouilles de blé dur1
Fertiggerichte, Fertigsalate, en:Caesar salads1
Auf Fleisch basierende Lebensmittel, Fleisch, Zubereitetes Fleisch, Würste1
Dietary supplements1
en:simple-syrups1
Alimentos y bebidas de origen vegetal, Alimentos de origen vegetal, Cereales y patatas, Cereales y derivados, Pastas alimenticias, en:Cereal pastas, Pasta de trigo duro, Espaguetis, Espaguetis de trigo duro1
Snacks, Sweet snacks, Biscuits and cakes, Cakes, Chocolate cakes, Brownies1
Meats and their products, Prepared meats, Cured sausages, Salami, italian meat products1
Dairies, Fermented foods, Fermented milk products, Cheeses, Italian cheeses, Stretched-curd cheeses, Mozzarella1
en:Sandwiches, en:Sandwiches filled with cold cuts, en:Bacon sandwiches1
Imbiss, Süßer Snack, Kakao und Kakaoprodukte, Süßwaren, Schokoladenkonfekt, Halloren Kugeln1
Condiments, Sauces, Groceries1
Meals, Pasta dishes1
Beverages, Alcoholic beverages, Distilled beverages, Hard liquors, Liqueurs1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Petit-déjeuners, Produits à tartiner, Pâtes à tartiner végétales, Produits à tartiner sucrés, Confitures et marmelades, Confitures, Confitures d'abricot1
Färdigmat, Pastarätter, en:Prepared salads, en:Pasta salads, en:Salads with meat, en:Pasta salad with meat1
Växtbaserad mat och dryck, Växtbaserad mat, Färdigmat, Pastarätter, Pasta, en:Stuffed pastas, Tortelloni1
Produits de la mer, Poissons, Poissons maigres, Filets de poissons, Morues, Filets de cabillaud1
Viandes et dérivés, Viandes, Poulet et dérivés, Volailles, Poulets, Volailles cuites, Poulets cuisinés, Poulets rôtis2
Boissons, Boissons alcoolisées, Vins, Vins mutés, Vins français, Mistelle, Pineau des Charentes1
Sauce d'ail1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Condiments, Produits à tartiner, Pâtes à tartiner végétales, Produits à tartiner salés, Sauces, Trempettes, Houmous1
Meats and their products, Prepared meats, Cured sausages, Salami1
Pflanzliche Lebensmittel und Getränke, Pflanzliche Lebensmittel, Getreide und Kartoffeln, Brotaufstriche, Getreideprodukte, Pflanzliche Brotaufstriche, Ölsaaten-Pürees, en:Cereal butters, Tahin1
pl:Herbatniki, en:biscuits1
Viandes et dérivés, Viandes, Poulet et dérivés, Volailles, Poulets, Volailles cuites, Cuisses de poulet, Poulets cuisinés, Cuisse de poulet rôtie avec viande et peau1
Condiments, Salts, Groceries1
Produits de la mer, Produits à tartiner, Produits à tartiner salés, Taramas, Tarama au corail d'oursin1
Meats and their products, Meats, Chicken and its products, Poultries, Chickens, Chicken wings, Ro 208 ec1
Viandes et dérivés, Viandes, Préparations de viande, Volailles, Dinde et dérivés, Produits panés, Volailles cuites, Dindes, Escalopes de viande panées, Escalopes de dinde, Préparations à la dinde, Dindes panées, Escalopes de dinde panées, Escalopes, Escal3
Viandes et dérivés, Viandes, Volailles, Canards, Filets de canard1
Viandes et dérivés, Viandes, Préparations de viande, Volailles, Dinde et dérivés, Produits panés, Volailles cuites, Dindes, Escalopes de viande panées, Escalopes de dinde, Préparations à la dinde, Dindes panées, Escalopes de dinde panées1
Desserts, Surgelés, Desserts glacés, Glaces et sorbets, Sorbets, Sorbets à la fraise1
Meals, Pasta dishes, Stuffed pastas, Ravioli1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Céréales et pommes de terre, Céréales et dérivés, Pâtes à tarte, Pâtes brisées1
Surgelés, Plats préparés, Pizzas tartes salées et quiches, Pizzas et tartes surgelées, Tartes salées surgelées1
Viandes et dérivés, Viandes, Poulet et dérivés, Volailles, Poulets, Filets de poulet, Poulets fermiers1
Cibi e bevande a base vegetale, Cibi a base vegetale, Legumi ed i loro prodotti, Farine, Farine di legumi, Farine di ceci1
Pflanzliche Lebensmittel und Getränke, Pflanzliche Lebensmittel, Imbiss, Getreide und Kartoffeln, Salzige Snacks, Vorspeisen, Chips und Pommes Frites, Chips, Kartoffelchips1
Snacks, Snacks sucrés, Confiseries, Bonbons1
Snacks, Snacks sucrés, Biscuits et gâteaux, Gâteaux, Gâteaux bretons, Gâteaux bretons aux pruneaux1
Produits de la mer,Poissons et dérivés,Poissons,Surgelés,Plats préparés,Poissons maigres,Plats préparés au poisson,Plats préparés surgelés,Plats préparés à réchauffer au micro-ondes,Colins,Lieu d'Alaska cru,Colins d'Alaska sauce beurre citron,Colins prépa1
Plats préparés, Plats préparés au poisson, Plats préparés à réchauffer au micro-ondes, Plats à base de boulgour1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Plats préparés, Plats préparés d'origine végétale1
Viandes et dérivés, Plats préparés, Plats à base de pâtes, Plats préparés à la viande, Plats au bœuf1
Viandes et dérivés, Plats préparés, Plats préparés à la viande, Plats à la volaille, Plats au poulet, Tajines de poulet1
en:rum-baba1
en:Plats préparés, en:Plats préparés à la viande, en:Produits à la viande1
Snacks, Sweet snacks, Biscuits and cakes, Biscuits, Chocolate biscuits, Milk chocolate biscuits1
Snacks, Snacks sucrés, Biscuits et gâteaux, Biscuits, Biscuits sablés1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Céréales et pommes de terre, Graines, Céréales et dérivés, Céréales en grains, Quinoa, Quinoa blanc1
Condiments, Sauces, Dips, Groceries1
en:dried-apricots1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Graines, Produits de la plante de courge, Graines de cucurbitacées, Graines de courge et dérivés, Graines de courge, Graines de courge décortiquées1
Aliments et boissons à base de végétaux, Boissons, en:Orange-flavoured beverages1
Zuivelproducten, Gefermenteerde levensmiddelen, Desserts, Gefermenteerde zuivelproducten, Desserts op basis van melk, Kwark, Magere kwarks1
Dairies, Fermented foods, Desserts, Fermented milk products, Dairy desserts, Fermented dairy desserts, Yogurts1
Getränke1
Dietary supplements,Bodybuilding supplements,Protein bars1
Viandes et dérivés, Plats préparés, Plats préparés à la viande1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Bouillons, Bouillons de légumes1
Snacks, Snacks sucrés, Barres, Compléments alimentaires, Compléments pour le Bodybuilding, Barres énergétiques, Barres protéinées, Barres énergétiques protéinées1
Fruits à coques1
Aliments et boissons à base de végétaux, Boissons, Aliments d'origine végétale, Boissons chaudes, Cafés, Boissons instantanées, Dosettes, Cafés en dosettes1
Snacks, Sweet snacks, Cocoa and its products, Confectioneries, Chocolate candies, Baking decorations1
Snacks, Snacks sucrés, Barres, Barres de céréales1
Compléments alimentaires1
Plant-based foods and beverages, Fermented foods, Dairy substitutes, Desserts, Non-dairy desserts, Non-dairy fermented foods, Non-dairy yogurts1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Petit-déjeuners, Céréales et pommes de terre, Céréales et dérivés, Céréales pour petit-déjeuner1
Aliments et boissons à base de végétaux, Boissons, Boissons à base de végétaux, Boissons gazeuses, Boissons aux fruits, Sodas, Sodas aux fruits, Sodas à l'orange, Boissons avec sucre ajouté1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Desserts, Fruits et produits dérivés, Compotes, Compotes de pomme1
Boissons, Sirops, Sirops aromatisés, Sirops de cassis, Boissons avec sucre ajouté1
Boissons, Sirops, Sirops aromatisés, Sirops d'orgeat, Boissons avec sucre ajouté1
Candies1
Boissons, Produits laitiers, Produits déshydratés, Laits, Produits lyophilisés à reconstituer, Boissons lyophilisées, Laits écrémés, Laits en poudre1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Céréales et pommes de terre, Pains, Pains azymes1
Bonbons de chocolat1
Milchprodukte, Fermentierte Lebensmittel, Fermentierte Milch, Käse, Kuhmilchkäse, Ungekochter gepresster Käse, Holländischer Käse, Goudas1
Snacks, Snacks salés, Amuse-gueules, Sandwichs, Hamburgers1
Snacks, Snacks salés1
Aliments et boissons à base de végétaux, Boissons, Aliments d'origine végétale, Cafés, Surgelés1
Condiments, Sauces, Tomato sauces, Ketchup, Groceries1
Beverages, Energy drinks, Sweetened beverages1
Produits laitiers, Produits fermentés, Produits laitiers fermentés, Fromages, Fromages à pâte pressée cuite, Fromages de France, Comté, en:aoc-cheeses, en:labeled-cheeses3
Produits laitiers, Produits fermentés, Produits laitiers fermentés, Fromages, Fromages à pâte pressée cuite, Fromages de vache, Emmentals, Fromages de France, Emmentals français, Emmentals de Savoie1
Produits laitiers,Produits fermentés,Produits laitiers fermentés,Fromages,Fromages de vache,Fromages à pâte pressée cuite,Emmentals,Fromages de France,Emmentals français,Emmentals de Savoie1
Produits laitiers, Produits fermentés, Produits laitiers fermentés, Fromages, Fromages de France, Fromages à pâte pressée non cuite, Fromages de brebis, Ossau-Iraty2
Productos del mar, Conservas, Pescados, en:Fatty fishes, Conservas de pescado, Atunes, Atun en conserva, Atún en aceite, Atún en aceite de oliva, Atún claro en aceite de oliva1
Produits laitiers, Produits fermentés, Produits laitiers fermentés, Fromages, Fromages à pâte persillée, Fromages à pâte persillée français, Fromages de brebis, Roqueforts1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Légumineuses et dérivés, Conserves, Légumineuses, Graines, Légumes et dérivés, Aliments à base de plantes en conserve, Graines de légumineuses, 1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Légumineuses et dérivés, Conserves, Légumineuses, Légumes et dérivés, Aliments à base de plantes en conserve, Légumes, Légumes en conserve, Légu1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Légumineuses et dérivés, Conserves, Légumineuses, Graines, Aliments à base de plantes en conserve, Graines de légumineuses, Légumineuses sèches, Pois chiches, Légumineuses en conserve, 1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Légumineuses et dérivés, Conserves, Légumineuses, Légumes et dérivés, Aliments à base de plantes en conserve, Légumes en conserve, Légumineuses 1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Snacks, Conserves, Snacks salés, Légumes et dérivés, Amuse-gueules, Aliments à base de plantes en conserve, Plats préparés, Légumes en conserve,1
Plant-based foods and beverages, Plant-based foods, Fats, Vegetable fats, Olive tree products, Vegetable oils, Olive oils, Extra-virgin olive oils, Virgin olive oils1
en:Plant-based foods and beverages, Kvašené potraviny, en:Dairy substitutes, en:Desserts, en:Non-dairy desserts, en:Non-dairy fermented foods, en:Non-dairy yogurts1
Beverages, Carbonated drinks, Sodas, Colas1
Mausteet, Kastikkeet, Dipit, en:groceries1
Aliments et boissons à base de végétaux, Boissons, Boissons à base de végétaux, Boissons aux fruits, Jus et nectars, Nectars de fruits, Nectars de mangue1
Snacks, Sweet snacks, Confectioneries, Candies1
es:Tortillas de harina, en:wheat-flours1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Légumineuses et dérivés, Légumineuses, Légumes et dérivés, Surgelés, Légumes, Aliments à base de plantes surgelés, Légumineuses surgelées, Légum1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Plats préparés, Plats à base de pâtes, Pâtes alimentaires, Pâtes farcies, Tortellini, Tortellini ricotta & épinards, Traiteur1
Plant-based foods and beverages, Plant-based foods, Cereals and potatoes, Breads, Special breads, Bagel breads1
Eis am Stiel Mischpackungen1
Milchprodukte, Fermentierte Lebensmittel, Desserts, Fermentierte Milch, Milchnachspeisen, en:Fermented dairy desserts, Milchdesserts1
Condiments, Sauces, Pestos, Red pestos1
sun dried tomatoes1
en:potatoes1
Fats, Spreads1
Beauty & Personal Care10
Vitamins & Supplements2
Food & Beverages19
Active Lifestyle & Fitness4
Herbs, Botanicals & Homeopathy1
Weight Management2
Baby & Kids Products1
Professional Supplements1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Cilantro pureePlant-based foods and beverages, Plant-based foods, Fruits and vegetables based foodscalcium ascorbate2024-02-12
Good & gather mild cheddar cheese extra thin slicesDairies, Fermented foods, Fermented milk products, Cheesesannatto2024-02-12
Jumbo raw shell & tail on ez peel wild caught argentine red shrimpSeafood, Frozen foods, Frozen seafoodsodium carbonate2024-02-12
Orange fudge dipped pretzel rods with white fudge drizzle, orange fudgeSnacksriboflavin,niacin2024-02-12
Pancakes & SausageOtherriboflavin,sodium bicarbonate,niacin2024-02-13
Same sweetener* as sweet'n low saccharinSweeteners, Sugarscalcium silicate2024-02-12
Fibre One 90 -Chocolate Fudge BrowniesGeneral MillsSnacks, Sweet snacks, Biscuits and cakes, Cakes, Chocolate cakes, Browniessodium bicarbonate2024-02-13
Mac 'N' Cheese DinnerHannaford Bros. Co.Meals, Pasta dishesniacin,ferrous sulfate,riboflavin2024-02-09
mixitka brownie a proteinmixitDietary supplements,Bodybuilding supplements,Protein barsglycerol2024-04-16
Barre Flocon d'Avoine et Whey Caramel SaléMyproteinSnacks, Snacks sucrés, Barres, Compléments alimentaires, Compléments pour le Bodybuilding, Barres énergétiques, Barres protéinées, Barres énergétiques protéinéesmaltitol2024-02-10
Three friendsOhoAliments et boissons à base de végétaux, Aliments d'origine végétale, Petit-déjeuners, Céréales et pommes de terre, Céréales et dérivés, Céréales pour petit-déjeunerthiamine2024-08-22
Energy DrinkRed Bull,RedBullBeverages, Energy drinks, Sweetened beveragesriboflavin,caffeine,taurine2024-06-19
ChardonnayThe real wine gumSnacks, Sweet snacks, Confectioneries, Candieslactic acid2024-02-11
Western family, spreadWestern Family, Marca RegistradaFats, Spreadsbeta carotene,sodium benzoate2024-02-09
Acure Seriously Soothing Day Cream -- 1.7 fl ozAcureBeauty & Personal Carecetearyl alcohol, glyceryl stearate, glycerin, glyceryl laurate, glyceryl caprylate, tocopherols2024-11-29 10:47:42
Avalon Organics Vitamin C Gel Cream Moisturizer -- 1.7 ozAvalon OrganicsBeauty & Personal Careorange, ascorbyl glucoside, ascorbic acid, benzoic acid, calcium ascorbate, beta-glucan, glycerin, limonene, sodium benzoate, sorbic acid, squalane, tocopherols2024-11-29 10:47:42
Avalon Organics Vitamin C Renewal Crème Riche -- 1.7 ozAvalon OrganicsBeauty & Personal Careorange, ascorbyl glucoside, ascorbic acid, calcium ascorbate, cetyl alcohol, glyceryl stearate, glycerin, limonene, glyceryl caprylate, squalane, stearyl alcohol, tocopherols2024-11-29 10:47:42
Beauty Without Cruelty Hand and Body Lotion Vitamin C with CoQ10 -- 8.5 fl ozBeauty Without CrueltyBeauty & Personal Careallantoin, chamomile, ascorbic acid, kelp, cetyl alcohol, CoQ-10, panthenol, palmarosa, glycerin, dimethicone, phenoxyethanol, sodium cocoyl glutamate, sorbitol, stearic acid, tocopherols2024-11-29 10:47:42
Every Man Jack Beard Oil - Sandalwood -- 1 fl ozEvery Man JackBeauty & Personal Caretocopherols2024-11-29 10:47:42
Green Goo Plants For Your Face All Over Face + Body Wash Eczema -- 4 fl ozGreen GooBeauty & Personal Caregeranium, chamomile, calendula, vitamin E, palmarosa, vitamin E, tocopherols2024-11-29 10:47:42
Greens First PRO Ahiflower Oil Vegan Omega-3 -- 90 SoftgelsGreens FirstVitamins & SupplementsLinolenic Acid, Stearidonic Acid, Gamma Linolenic Acid, glycerin, Oleic Acid, tocopherols2024-11-29 10:47:42
Jarrow Formulas Krill Oil -- 120 SoftgelsJarrow FormulasVitamins & SupplementsAstaxanthin, EPA, glycerin, tocopherols2024-11-29 10:47:42
Jovial Organic Gluten Free Dairy Free Vegan Mac -- 6 ozJovialFood & Beveragescitric acid, citric acid, tocopherols2024-11-29 10:47:42
MRM Natural Gainer Rich Vanilla -- 3.3 lbsMRMActive Lifestyle & FitnessAlanine, Arginine, Vitamin C, Aspartic Acid, Cysteine, Glutamic Acid, Glycine, Histidine, Isoleucine, Leucine, Lysine, maltodextrin, Methionine, Phenylalanine, Proline, Vitamin A, Serine, Threonine, tocopherols, trehalose, tricalcium phosphate, Tryptophan, Tyrosine, Valine2024-11-29 10:47:42
Namaste Foods Blondie Mix Gluten Free -- 15 ozNamaste FoodsFood & Beverages Cane sugar, tocopherols2024-11-29 10:47:42
Namaste Foods Gluten Free Muffin & Scone Mix -- 16 ozNamaste FoodsFood & Beveragesbaking soda, cane sugar, tocopherols2024-11-29 10:47:42
Namaste Foods Gluten Free No Sugar Added Muffin Mix -- 14 ozNamaste FoodsFood & BeveragesVitamin C, Fat, Vitamin A, baking soda, tocopherols2024-11-29 10:47:42
Namaste Foods Waffle & Pancake Mix Gluten Free -- 21 ozNamaste FoodsFood & BeveragesVitamin C, Vitamin A, baking soda, tocopherols2024-11-29 10:47:42
One Degree Organic Foods Gluten Free Sprouted Granola Vanilla Chia -- 11 ozOne Degree Organic FoodsFood & Beveragesvitamin E, Folate, vitamin E, Manganese, Phosphorus, Thiamin, tocopherols2024-11-29 10:47:42
One Degree Organic Foods Gluten Free Tea Infused Granola Sprouted Cacao Mint -- 10 ozOne Degree Organic FoodsFood & Beveragesvitamin E, vitamin E, tocopherols2024-11-29 10:47:42
One Degree Organic Foods Gluten Free Tea Infused Granola Sprouted Coconut Hibiscus -- 10 ozOne Degree Organic FoodsFood & BeveragesVitamin E, Vitamin E, tocopherols2024-11-29 10:47:42
One Degree Organic Foods Gluten Free Tea Infused Granola Sprouted Honey Bergamot -- 10 ozOne Degree Organic FoodsFood & BeveragesVitamin E, Vitamin E, tocopherols2024-11-29 10:47:42
One Degree Organic Foods Organic Sprouted Granola Cinnamon Flax -- 11 ozOne Degree Organic FoodsFood & Beveragesvitamin E, Folate, vitamin E, Manganese, Phosphorus, Thiamin, tocopherols2024-11-29 10:47:42
One Degree Organic Foods Organic Sprouted Oat Granola Honey Hemp -- 11 ozOne Degree Organic FoodsFood & Beveragesvitamin E, Folate, vitamin E, Manganese, Phosphorus, Thiamin, tocopherols2024-11-29 10:47:42
One Degree Organic Foods Organic Sprouted Oat Granola Quinoa Cacao -- 11 ozOne Degree Organic FoodsFood & Beveragesvitamin E, vitamin E, Manganese, Phosphorus, tocopherols2024-11-29 10:47:42
One Degree Organic Foods Sprouted Brown Rice Cacao Crisps Cacao -- 10 ozOne Degree Organic FoodsFood & Beveragesvitamin E, Folate, vitamin E, Manganese, Niacin, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, tocopherols, Vitamin B62024-11-29 10:47:42
One Degree Organic Foods Sprouted Brown Rice Crisps Cereal -- 8 ozOne Degree Organic FoodsFood & Beveragesvitamin E, Folate, vitamin E, Manganese, Niacin, Phosphorus, Vitamin B6, Riboflavin, Selenium, Thiamin, tocopherols, Vitamin B62024-11-29 10:47:42
Optimum Nutrition Gold Standard 100% Whey Protein Powder For Muscle Support and Recovery Chocolate Peanut Butter -- 22 ServingsOptimum NutritionActive Lifestyle & Fitnessacesulfame potassium, acesulfame potassium, tocopherols, tricalcium phosphate2024-11-29 10:47:42
Optimum Nutrition Gold Standard 100% Whey Protein Powder For Muscle Support and Recovery Extreme Milk Chocolate -- 28 ServingsOptimum NutritionActive Lifestyle & Fitnessacesulfame potassium, acesulfame potassium, maltodextrin, tocopherols, tricalcium phosphate2024-11-29 10:47:42
Optimum Nutrition Gold Standard 100% Whey Protein Powder For Muscle Support and Recovery Extreme Milk Chocolate -- 71 ServingsOptimum NutritionActive Lifestyle & Fitnessacesulfame potassium, acesulfame potassium, Vitamin C, maltodextrin, Vitamin A, tocopherols, tricalcium phosphate, sucralose2024-11-29 10:47:42
Pacifica Rosemary Purify Invigorating Conditioner -- 8 fl ozPacificaBeauty & Personal Carecetearyl alcohol, cetyl alcohol, vitamin E, panthenol, ethylhexylglycerin, vitamin E, glycerin, menthol, vitamin B5, sodium benzoate, sorbitol, stearyl alcohol, tocopherols2024-11-29 10:47:42
Simple Truth Gluten Free Rice & Almond Thin Crackers Vegan Parmesan Style Seasoning -- 3.5 ozSimple TruthFood & Beveragescitric acid, citric acid, maltodextrin, cane sugar, tocopherols2024-11-29 10:47:42
Simple Truth Organic Toasted Oas Cereal Honey Nut -- 12.2 ozSimple Truth OrganicFood & Beveragescalcium carbonate, tocopherols2024-11-29 10:47:42
Simple Truth Organic Toasted Oats Cereal Whole Grain -- 12 ozSimple Truth OrganicFood & Beveragescalcium carbonate, tocopherols2024-11-29 10:47:42
Stonewall Kitchen Aioli All Natural Horseradish -- 10.25 ozStonewall KitchenFood & Beveragescitric acid, vinegar, Vitamin C, citric acid, Vitamin A, tartaric acid, Tocopherols2024-11-29 10:47:42
Stonewall Kitchen All Natural Aioli Roasted Garlic -- 10.25 ozStonewall KitchenFood & BeveragesVitamin C, Vitamin A, Tocopherols2024-11-29 10:47:42
Terry Naturally Omega-7 Dry Eye Relief -- 60 SoftgelsTerry NaturallyHerbs, Botanicals & HomeopathyOmega-3, glycerol, tocopherols, tocotrienols2024-11-29 10:47:42
think! High Protein Bars White Chocolate -- 10 Barsthink!Weight ManagementVitamin C, glycerin, maltitol, Vitamin A, Sugar, tocopherols2024-11-29 10:47:42
think! Keto Protein Bars Chocolate Peanut Butter Cookie Dough -- 10 Barsthink!Weight Managementerythritol, tocopherols2024-11-29 10:47:42
ThinkKids Sunscreen Lotion Clear Zinc SPF 50 -- 6 fl ozThinkKidsBaby & Kids Productsascorbic acid, vitamin E, vitamin E, magnesium sulfate, tocopherols2024-11-29 10:47:42
Thinksport Everyday Face SPF 30 plus -- 2 fl ozThinksportBeauty & Personal Careascorbic acid, magnesium sulfate, tocopherols2024-11-29 10:47:42
Thinksport Sunscreen SPF 50 plus -- 3 fl ozThinksportBeauty & Personal Careascorbic acid, vitamin E, vitamin E, dimethicone, magnesium sulfate, methyl abietate, tocopherols2024-11-29 10:47:42
Vital Nutrients Ultra Pure Fish Oil 700 - General Health Maintenance Inflammatory Balance Joint & Cartilage -- 120 SoftgelsVital NutrientsProfessional SupplementsEPA, glycerin, tocopherols2024-11-29 10:47:42
Zion Health Daily Lotion Mineral Moisture White Coconut -- 8 fl ozZion HealthBeauty & Personal Carechamomile, benzyl alcohol, cetyl alcohol, ethyl hexyl glycerin, glyceryl stearate, glycerin, phenoxyethanol, montmorillonite clay, sodium cocoyl glutamate, stearic acid, tocopherols2024-11-29 10:47:42

Bioassays (2)

Assay IDTitleYearJournalArticle
AID86701Compound evaluated for percent inhibition of cholesterol synthesis from [14C]acetate in HepG2 cell1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Hypocholesterolemic activity of synthetic and natural tocotrienols.
AID86700Compound evaluated for percent inhibition of cholesterol synthesis from HMG-CoA Reductase in HepG2 cell1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Hypocholesterolemic activity of synthetic and natural tocotrienols.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,159)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990460 (14.56)18.7374
1990's239 (7.57)18.2507
2000's1058 (33.49)29.6817
2010's1062 (33.62)24.3611
2020's340 (10.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 81.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index81.57 (24.57)
Research Supply Index8.17 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index191.30 (26.88)
Search Engine Supply Index2.58 (0.95)

This Compound (81.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials181 (5.40%)5.53%
Reviews237 (7.07%)6.00%
Case Studies39 (1.16%)4.05%
Observational2 (0.06%)0.25%
Other2,895 (86.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (169)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and Efficacy of the Ascorbic Acid and Tocopherol for the Treatment of the Fragile X Syndrome [NCT01329770]Phase 230 participants (Actual)Interventional2010-12-31Completed
The Effect of Antioxidant Vitamin Supplementation on Muscle Performance and Redox Status After Eccentric Training [NCT01290458]28 participants (Actual)Interventional2009-06-30Completed
Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD [NCT04801849]Phase 2200 participants (Anticipated)Interventional2022-08-05Recruiting
A Phase II Randomized, Double Blinded, Placebo-controlled Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults [NCT03444298]Phase 223 participants (Actual)Interventional2018-06-08Completed
Efficacy of Vitamin C, Vitamin E and Their Combination for Treatment of Restless Legs Syndrome in Hemodialysis Patients: a Randomized Double-blind, Placebo-controlled Trial [NCT01125033]Phase 2/Phase 360 participants (Actual)Interventional2008-03-31Completed
Malaysian Tocotrienol Rich Fraction: Immunomodulatory Effect in Women With Breast Cancer [NCT03855423]12 participants (Anticipated)Interventional2019-02-18Recruiting
Effects of Long-term Vitamin C+E and Statin Therapy on Vasospasm Improvement and Regression of Atheroma in Patients With Variant Angina [NCT03228238]Phase 4300 participants (Anticipated)Interventional2014-09-01Recruiting
Effects of Supplementation With Tocotrienol on Inflammation, Oxidative Stress and Microbiota of Chronic Kidney Disease Patients [NCT04900532]61 participants (Actual)Interventional2019-05-01Active, not recruiting
A Phase 2, Randomized Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis (NASH) [NCT04134091]Phase 256 participants (Actual)Interventional2019-08-27Completed
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure [NCT02911688]Phase 218 participants (Actual)Interventional2016-09-30Completed
A Randomized, Double-blinded, Parallel, Placebo-controlled Pilot Study to Investigate the Effect of Nutrition Ingredients on Microbiota Composition in Healthy Adults [NCT03668964]96 participants (Actual)Interventional2018-08-20Completed
A 4-month, Randomized, Placebo-controlled, Double-blind Intervention of Antioxidant Supplementation in Overweight Children Enrolled in an Outpatient Weight-loss Program: Effects on Oxidative and Inflammatory Markers, Hepcidin, Iron Status, and Components [NCT01316081]45 participants (Actual)Interventional2011-03-31Completed
Effectiveness of Tocotrienol-rich Fraction Combined With Tamoxifen in the Management of Women With Early Breast Cancer: A Pilot Clinical Trial [NCT01157026]240 participants (Actual)Interventional2001-11-30Completed
Application of Vitamin E Acetate Ointment vs Nitroglycerin Ointment for the Treatment of Chronic Anal Fissure [NCT03787030]Phase 3160 participants (Actual)Interventional2018-12-21Completed
A Randomized Double-Blind Placebo-Controlled Study Of Oral Coenzyme Q10 To Relieve Self-Reported Cancer Treatment Related Fatigue In Breast Cancer Patients [NCT00096356]Phase 1236 participants (Actual)Interventional2004-08-27Completed
Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer: A Marker Based Phase II Trial [NCT04175470]Phase 260 participants (Anticipated)Interventional2019-10-29Recruiting
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer [NCT00006392]Phase 335,533 participants (Actual)Interventional2001-07-31Completed
Preoperative Use of Tocotrienol Associated With Personalized Nutritional and Psychoeducational Support in Women With Primary Breast Cancer. [NCT04496492]Phase 250 participants (Actual)Interventional2016-02-09Completed
Cardioprotective Synergy of Smoking Cessation and γ-Tocopherol in Restoring Vascular Endothelial Function [NCT01314443]Phase 1/Phase 267 participants (Actual)Interventional2011-01-31Completed
Vitamin E Supplementation in Hyperinsulinism/Hyperammonemia Syndrome [NCT03797222]14 participants (Actual)Interventional2019-04-15Completed
Photobiomodulation With Low Level Laser in the Prevention and Treatment of Oral Lesions (Mucositis, Hyposalivation and Osteonecrosis) Resulting From Anti-neoplastic Treatment With Chemotherapy or Radiotherapy. [NCT04717765]60 participants (Actual)Interventional2021-02-10Completed
Vitamins C and Vitamin E and Hypertrophy Adaptations to Resistance Traini [NCT04828642]30 participants (Actual)Interventional2021-02-01Completed
Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL): a First-in-men Study [NCT02251041]Phase 272 participants (Actual)Interventional2014-09-30Completed
Phase III, Single Centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Oral Vitamin E (Mixed Tocotrienol) for 6 Months in Patients With Moderate Acute Ischemic Stroke [NCT02263924]Phase 3150 participants (Anticipated)Interventional2015-07-31Recruiting
Antioxidant Micronutrients in Malaria:a Randomised Clinical Trial [NCT01152931]Phase 310 participants (Actual)Interventional2010-08-31Completed
The Effect of Alpha-tocopherol in Hemolysis and Oxidative Stress Marker on the Red Cell [NCT03948737]40 participants (Actual)Interventional2016-12-30Completed
Mechanism of Absorption and Distribution of Tocotrienols Under Different Food Status [NCT01185769]10 participants (Actual)Interventional2009-09-30Completed
Evaluating the Effect of Vitamin E Treatment on HDL Function of Type 2 Diabetic Patients and the Correlation to Hp Phenotype. A Prospective, Double Blind, Randomized, Placebo Controlled Trial (IDEAL2 Study) [NCT01113671]Phase 2/Phase 390 participants (Anticipated)Interventional2009-01-31Completed
A Double Blind Placebo Controlled Study On The Neuroprotective And Anti-Atherogenic Effects Of Palm TocotrienolRich Fraction(Palm Vitamin E) [NCT00753532]Phase 2241 participants (Actual)Interventional2007-11-30Completed
Randomized Clinical Trial Evaluating Combined Pentoxifylline-tocopherol-clodronate vs Placebo in Radiation-induced Brachial Plexopathy: the PENTOCLO Trial [NCT01291433]Phase 359 participants (Actual)Interventional2011-03-31Completed
Effect of the Application of Vitamin E Ointment, Over Staple Lines and Anastomosis in Roux-en-Y Gastric Bypass, on Postoperative Pain [NCT03765827]Phase 3140 participants (Actual)Interventional2018-12-05Completed
Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible, a Pilot Randomized Control Trial [NCT06055257]Phase 324 participants (Anticipated)Interventional2023-12-15Not yet recruiting
NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment [NCT01002547]Phase 4105 participants (Actual)Interventional2010-06-24Completed
Effect of Subcutaneous Sterile Vitamin E Ointment on Incisional Surgical-site Infection Following Elective Laparoscopic Colorectal Cancer Surgery [NCT02820948]Phase 3108 participants (Actual)Interventional2015-01-31Completed
Phase II, Double-blind, Randomized, 1-way Cross-over, to Investigate the Effectiveness of the Combination of Ascorbic Acid (Vitamin C) and Tocopherol (Vitamin E) Versus Placebo for the Treatment of Depressive Disorders in Elderly [NCT02793648]Phase 250 participants (Actual)Interventional2014-10-31Completed
Effect of Intravenous Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function in Patients With Colon Cancer [NCT02231203]Phase 444 participants (Actual)Interventional2014-10-31Completed
Effects of a Tocotrienol-Enriched Fraction of Palm Oil and Chinese Red Yeast Rice on Serum Lipids in Hypercholesterolemic Subjects [NCT02142569]Phase 2/Phase 30 participants (Actual)Interventional2013-10-30Withdrawn(stopped due to We were unable to procure the supplement for this study.)
[NCT02070679]Phase 3284 participants (Actual)Interventional2014-02-28Completed
Phase 1b to Assess Safety, Tolerability, Pharmacokinetic Profile, and Antimalarial Activity of Single Doses of Co-administered OZ439and PQP Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Adult Volunteers [NCT03542149]Phase 124 participants (Actual)Interventional2018-04-23Completed
A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E [NCT05939726]90 participants (Anticipated)Interventional2023-05-16Recruiting
Comprehensive Assessment of Indices of Apoptosis and Endothelial Dysfunction and Methods of Their Correction in Patients With Atherosclerosis of Peripheral Arteries [NCT04502849]250 participants (Actual)Observational2020-01-01Completed
"Cardiac Transfer of SARS-CoV-2 Spike Protein Circulation Techniques - Medicine Induced Hemodialysis on Vaccinated Immune Attacks" [NCT05711810]Phase 41 participants (Actual)Interventional2023-01-02Completed
Pilot and Feasibility Study for a Pharmacogenomic Trial in Type 1 Diabetes [NCT01098994]87 participants (Actual)Interventional2010-02-28Completed
Anti-Inflammatory Effect of Tocotrienol Supplementation in Subjects With Moderately Elevated Inflammation [NCT03532763]180 participants (Anticipated)Interventional2018-04-19Recruiting
Effect of Gamma Tocopherol Supplementation on Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Normal Adults [NCT00631085]Phase 118 participants (Actual)Interventional2008-05-31Completed
Interventional Strategy in Tackling Emerging Non-alcoholic Fatty Liver Disease in Childhood Obesity [NCT05905185]Phase 429 participants (Actual)Interventional2020-01-01Completed
A Randomized Investigation of Side Effects to FOLFOXIRI in Combination With Tocotrienol or Placebo as First Line Treatment of Metastatic Colorectal Cancer [NCT02705300]Phase 270 participants (Actual)Interventional2016-05-06Active, not recruiting
"The Effect of KB-120 Small Molecular Nutrient in Women With Decreased Ovarian Reserve" [NCT06081257]80 participants (Anticipated)Interventional2023-10-15Not yet recruiting
Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial [NCT02776397]300 participants (Anticipated)Interventional2015-06-30Recruiting
A Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia [NCT00985777]Phase 126 participants (Actual)Interventional2009-09-30Completed
Efficacy of Alpha Tocopherol and New Biomarker (Urine NGAL) for Prevention and Early Diagnosis of Contrast-induced Nephropathy in CKD Patients Undergoing Elective Coronary Procedures [NCT01061320]Phase 3200 participants (Anticipated)Interventional2010-01-31Enrolling by invitation
PentoxIfylline and Tocopherol for the Treatment of Post-radiotherapy Fibrosis in Head and Neck Cancer Patients: a Feasibility Study [NCT03723291]Phase 150 participants (Anticipated)Interventional2019-09-01Recruiting
Vitamin E Treatment for LCHAD Associated Neuropathy [NCT00840112]1 participants (Actual)Interventional2010-07-31Terminated(stopped due to New data does not support a role of vitamin E in LCHAD associated neuropathy.)
Osteoradionecrosis and PENTOCLO Protocol: Retrospective Study. [NCT04097847]96 participants (Actual)Observational2017-06-02Completed
Effects of Coenzyme Q10 in Parkinson Disease - Phase III [NCT00740714]Phase 3600 participants (Actual)Interventional2008-12-31Terminated(stopped due to The investigational drug is unlikely to demonstrate efficacy over placebo for this indication. However, no safety issues were discovered.)
In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics [NCT00836368]Phase 125 participants (Actual)Interventional2008-12-31Completed
Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application [NCT02758990]16 participants (Actual)Interventional2016-03-31Terminated(stopped due to Recruiting and financial constraints)
Evaluation of a Short Course of Gamma Tocopherol Supplementation in Adult Subjects [NCT02610829]10 participants (Actual)Interventional2015-11-30Completed
A Randomized Controlled Project to Study the Efficacy of Combined Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis [NCT01384578]Phase 30 participants (Actual)Interventional2011-07-31Withdrawn(stopped due to Lack of funds)
The PENTO Protocol in Medication-related Osteonecrosis of the Jaw [NCT05795647]Phase 217 participants (Anticipated)Interventional2023-11-20Not yet recruiting
Tocotrienol Against the Progression of End Stage Liver Disease [NCT02581085]Phase 270 participants (Anticipated)Interventional2019-11-01Recruiting
VEAPS: Vitamin E Atherosclerosis Prevention Study [NCT00114387]Phase 2/Phase 3353 participants Interventional1996-07-31Completed
Virtual Reality and Computerized Cognitive Intervention for Mild Cognitive Impairment in Heart Failure [NCT05601817]172 participants (Anticipated)Interventional2023-04-03Recruiting
Single-site, Open-label, Dose-ranging, Efficacy, and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated CF [NCT00889434]7 participants (Actual)Interventional2011-11-01Completed
The Effect of Supplemental Adjuvants for Intracellular Nutrition and Treatment on Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration [NCT00893724]60 participants (Anticipated)Interventional2009-06-30Active, not recruiting
CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD) [NCT00235716]Phase 3613 participants (Actual)Interventional2007-08-31Completed
Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL): a First-in-men Study [NCT01886443]Phase 110 participants (Actual)Interventional2013-08-31Completed
Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency [NCT05410093]150 participants (Anticipated)Interventional2022-02-01Recruiting
The Effect of Vitamin E and Docosahexaenoic Acid Ethyl Ester on Non-Alcoholic Fatty Liver Disease (NAFLD) - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD) [NCT04198805]Phase 2205 participants (Actual)Interventional2020-01-03Completed
A Clinical Study on the Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus [NCT01973400]Phase 3300 participants (Actual)Interventional2011-06-30Completed
[NCT02011906]Phase 420 participants (Anticipated)Interventional2013-10-31Enrolling by invitation
A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products [NCT02014922]Phase 433 participants (Actual)Interventional2013-12-31Completed
Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol [NCT00678834]Early Phase 180 participants (Actual)Interventional2006-03-31Completed
Actions of Dietary Tocotrienols on Obesity [NCT03705845]Phase 1/Phase 260 participants (Anticipated)Interventional2019-03-15Recruiting
Comparative Effects of Milk Thistle Extract With Vitamin-E on Oxidative Stress Biomarkers in Hemodialysis Patients [NCT01001845]Phase 280 participants (Anticipated)Interventional2009-06-30Completed
A Phase II Trial of a Combination Herbal Therapy for Men With Biochemical Recurrence of Prostate Cancer After Initial Local Therapy [NCT00669656]Phase 243 participants (Actual)Interventional2008-07-06Completed
Randomized, Placebo-controlled, Cross-over, Double-blind Study of a Metabolic Support Therapy With Q10 Ubiquinol and a Multivitamin B and E Complex in Two Cohorts of Patients With Idiopathic and Syndromic Autism (Phelan-McDermid Syndrome) [NCT04312152]200 participants (Anticipated)Interventional2019-03-09Enrolling by invitation
Tocotrienol as a Nutritional Supplement in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) [NCT02644252]Phase 379 participants (Actual)Interventional2016-01-31Terminated(stopped due to The trial was ended prematurely because of a poor accrual rate)
Lifestyle Intervention and Antioxidants in Children With Nonalcoholic Fatty Liver Disease: A Randomized, Controlled Trial [NCT00655018]Phase 2/Phase 390 participants (Actual)Interventional2003-01-31Completed
Hydroxytyrosol and Vitamin E in the Treatment of Children With Biopsy-proven NASH [NCT02842567]Phase 380 participants (Actual)Interventional2017-04-01Completed
Vitamin E Supplementation in Burn Patients [NCT01413620]Phase 10 participants (Actual)Interventional2011-08-31Withdrawn
Effects of a High-dose Concentrate of n-3 Fatty Acids or Corn Oil Introduced Early After an Acute Myocardial Infarction on Serum Triacylglycerol and High-density Lipoprotein (HDL)- Cholesterol [NCT01422317]Phase 3300 participants (Actual)Interventional1995-09-30Completed
Phase III Study Analyzing the Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss [NCT00400387]Phase 3449 participants (Actual)Interventional2006-11-30Completed
A Phase II Study of the Use of Pentoxifylline and a-Tocopherol in the Treatment of Chronic Breast Pain Associated With Breast Radiotherapy [NCT00188669]Phase 248 participants (Anticipated)Interventional2002-07-31Terminated(stopped due to date: August 2006. No annual renewal)
Tocotrienols Supplementation in School Going Children With Attention Deficit/Hyperactivity Disorder(ADHD) - A Randomized Controlled Trial [NCT01855984]Phase 2/Phase 3160 participants (Anticipated)Interventional2012-02-29Completed
Human Blood Outcomes Following Tocotrienol Supplementation - Nutrition Phase IIB NUTRITION PHASE IIB [NCT01858311]300 participants (Actual)Observational2013-03-31Completed
Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer [NCT02909751]Phase 280 participants (Actual)Interventional2016-09-14Completed
To Investigate the Effectiveness of Adjuvant Supplements Prior to in Vitro Fertilization Cycles [NCT05471453]90 participants (Anticipated)Interventional2022-03-02Recruiting
[NCT00531674]0 participants Interventional2005-09-30Completed
Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF [NCT02690064]13 participants (Actual)Interventional2015-04-30Active, not recruiting
Pentoxifylline, Atorvastatin, and Vitamin E (PAVE) as Treatment for Radiation-Induced Erectile Dysfunction [NCT03830164]Phase 214 participants (Actual)Interventional2019-11-20Completed
Effects of a Tocotrienol-Enriched Fraction of Palm Oil on Serum Lipids in Hypercholesterolemic Subjects [NCT02634606]Phase 313 participants (Actual)Interventional2011-03-22Terminated(stopped due to Unable to obtain supplement for this study. Unable to recruit.)
ASSESSMENT OF INTERMEDIATE ENDPOINT BIOMARKERS TO 13-CIS RETINOIC ACID WITH OR WITHOUT ALPHA TOCOPHEROL OR OBSERVATION [NCT00002586]Phase 296 participants (Actual)Interventional1993-01-31Completed
Comparison of Gamma-tocopherol Supplementation in Allergic Asthmatics and Normal Volunteers [NCT00386178]Phase 116 participants (Actual)Interventional2006-10-31Completed
Vitamin E Versus Vitamin E Plus Pentoxiphyllin in Patients With Nonalcoholic Steatohepatitis: A Prospective Randomized Clinical Trial [NCT01279434]0 participants (Actual)Interventional2012-01-31Withdrawn
Trace Element Replenishment Study in Hemodialysis Patients [NCT01473914]Phase 3150 participants (Actual)Interventional2012-11-30Completed
Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT) [NCT00308971]Phase 262 participants (Actual)Interventional2006-03-31Completed
A Multicentre, Placebo-controlled Trial of Eicosapentaenoic Acid (EPA) and Antioxidant Supplementation in the Treatment of Schizophrenia and Related Disorders [NCT00419146]Phase 2/Phase 399 participants (Actual)Interventional2001-09-30Completed
Tocotrienols Supplementation for Postmenopausal Women With Low Muscle Strength [NCT03708354]Phase 1/Phase 20 participants (Actual)Interventional2019-04-15Withdrawn(stopped due to Difficulties in Recruiting)
Beta-carotene and Alpha-tocopherol Chemoprevention of Second Primary Malignancies in Head and Neck Cancer Patients [NCT00169845]Phase 3540 participants (Actual)Interventional1994-10-31Completed
Vitamins C and E Combined With Cryotherapy on the Pain, Oxidative Stress and Inflammatory Response After Resistance Exercise Session in Untrained Volunteers [NCT02902315]26 participants (Actual)Interventional2017-01-04Completed
Evaluation of the Clinical Benefit of a Spa Care on the Evolution of Late Fibrosis After Postoperative Radiotherapy for Breast Cancer in Remission [NCT02898376]Phase 3142 participants (Anticipated)Interventional2018-12-31Not yet recruiting
A Phase II Study of the Use of Pentoxifylline and Vitamin E in the Treatment of Late Radiation Related Injuries [NCT00188552]Phase 250 participants (Anticipated)Interventional2002-07-31Terminated(stopped due to May 2007: No annual renewal)
Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements [NCT00466596]Phase 18 participants (Actual)Interventional2007-03-31Completed
Impact of Oral Versatile Antioxidants on Glaucoma Progression:Comparative Early Results [NCT01544192]Phase 360 participants (Actual)Interventional2008-04-30Completed
Efficacy and Safety of the Association With Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C [NCT00119119]Phase 3100 participants Interventional2002-02-28Terminated
Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE) [NCT00040378]4,246 participants (Actual)Observational2002-05-31Completed
Multicenter Vitamin E Trial in Aging Persons With Down Syndrome [NCT00056329]Phase 3350 participants (Actual)Interventional2002-04-30Active, not recruiting
The Respiratory Ancillary Study (RAS) to SELECT [NCT00063453]Phase 32,920 participants (Actual)Interventional2003-08-31Completed
A Parallel, Evaluator-Blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Two Marketed Topical Skin Protectants Containing Zinc Oxide in Children With Diaper Rash [NCT00219466]Phase 4112 participants (Actual)Interventional2005-06-30Completed
A Randomized Double Blind Placebo Controlled Clinical Trial Aim to Assess the Efficacy of Vitamin E Formulation (Tocopherol) in the Treatment of Chemotherapy Induced Stomatitis in Patients Undergoing Stem Cell Transplantation [NCT00162526]Phase 230 participants (Anticipated)Interventional2005-12-31Withdrawn(stopped due to the PI is no longer work at Hadassah)
Study of the Effect of Oral Supplementation With Vitamin E on Circulating Oxidative Markers, Hemodialysis Vascular Access Occlusion, and Clinical Events in Patients With End Stage Renal Failure Treated by Hemodialysis [NCT00410449]35 participants Observational2001-05-31Completed
S0000D: A Study of the Effect of Vitamin E and/or Selenium on Adenomatous Colorectal Polyps (ACP) in Participants Enrolled in SELECT [NCT00706121]Phase 38,094 participants (Actual)Interventional2008-06-30Completed
S0000B: Prevention of Cataract and Age-Related Macular Degeneration With Vitamin E and Selenium - SELECT Eye Endpoints (SEE) [NCT00784225]Phase 313,475 participants (Actual)Interventional2004-07-31Completed
Effect of Tocotrienols on Bone Health: A Pilot Study [NCT02058420]Phase 1/Phase 278 participants (Actual)Interventional2014-02-28Completed
DBPCR Clinical Trial for Treatment of Rhinitis With Intranasal Vitamin E [NCT00281307]10 participants (Actual)Interventional2005-12-07Terminated(stopped due to Due to a substantial response to placebo an interim analysis indicated the need for a larger than expected study population to achieve the level of significance)
Postoperative Vitamin Supplementation in Morbidly Obese Patient [NCT01609387]Phase 4300 participants (Actual)Interventional2011-07-31Completed
A Randomized Study of the Effect of Alpha-tocopherol (AT) on 13-cis-retinoic Acid (13-cRA) Toxicity in a Preliminary Chemoprevention Trial in Former and Current Smokers [NCT00003599]Phase 30 participants (Actual)InterventionalWithdrawn(stopped due to Withdrawn study.)
Effects of Tocotrienols Supplementation on Platelet Aggregation in Subjects With Metabolic Syndrome [NCT01631838]32 participants (Actual)Interventional2012-05-31Completed
Novel Anti-inflammatory Dietary Intervention to Improve the Metabolic Phenotype of Overweight and Obese 13-18 Year Old Adolescents - Insights Into Potential Genetic Susceptibility [NCT01665742]58 participants (Actual)Interventional2012-01-31Completed
A Randomized Placebo-controlled Double-blind Pilot / Phase II Study to Assess the Efficacy and Safety of HOV-12020 in Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) [NCT04658823]Phase 250 participants (Anticipated)Interventional2020-12-21Active, not recruiting
Enhancing Treatment of Iron Deficiency and Iron Deficiency Anemia With an Antioxidant, Vitamin E [NCT01700426]Phase 144 participants (Actual)Interventional2011-06-30Completed
Impact of Nutrient Supplementation on Breast Milk Levels of Lactating Women [NCT01747668]Phase 389 participants (Actual)Interventional2012-11-30Completed
Vitamin E Supplementation in Burned Patients [NCT01749371]Phase 2/Phase 331 participants (Actual)Interventional2013-02-28Completed
Treatment of Radiation-induced Fibrosis in the Upper Aerodigestive Tract Cancer by a Combination of Pentoxifylline-tocopherol and Hyperbaric Oxygen [NCT01822405]Phase 242 participants (Anticipated)Interventional2010-07-31Recruiting
Effects of Inclusion of Sunflower Oil, Vitamin E and Selenium in the Diet of Dairy Cows on Milk Composition and Its Influence on Nutrition and Health of Elderly [NCT02980094]132 participants (Actual)Interventional2011-08-31Completed
Advances in the Management of Mandibular Osteoradionecrosis: Pentoxifylline and Tocopherol as Medical Treatment [NCT02368457]Phase 424 participants (Actual)Interventional2016-02-29Completed
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Vitamin E δ-Tocotrienol Following Single Dose Administration in Healthy Subjects [NCT01446952]Phase 118 participants (Actual)Interventional2011-09-30Completed
Quantitative Evaluation of the Effect of Dehydration and Rehydration Levels on Tooth Color Using Various Measurement Techniques [NCT05620277]30 participants (Anticipated)Interventional2022-06-05Enrolling by invitation
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Vitamin E δ-Tocotrienol Following Multiple Dose Administration in Healthy Subjects [NCT01450046]Phase 118 participants (Actual)Interventional2011-10-31Completed
Study of the Absorption of Vitamin E Water-soluble Form (Pegylated) in the Familial Hypocholesterolemia With Chylomicron Retention [NCT01457690]Phase 314 participants (Actual)Interventional2011-10-31Completed
A Phase III Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer Prior to Prostatectomy or Brachytherapy [NCT00809458]Phase 315 participants (Actual)Interventional2008-09-30Terminated(stopped due to Low rate of accrual.)
A Randomized, Double-Blind, Placebo-Controlled Study, to Assess the Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL) [NCT04704063]Phase 2170 participants (Anticipated)Interventional2021-01-01Active, not recruiting
Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ): A Prospective, Randomized Controlled Trial to Evaluate a Novel Non-operative Treatment [NCT03040778]Phase 3100 participants (Anticipated)Interventional2018-04-01Enrolling by invitation
Palm Tocotrienols in Chronic Hemodialysis (PATCH Study) [NCT02358967]280 participants (Actual)Interventional2017-06-15Completed
Prospective, Randomized, Single-blind, Multinational, Long-term Study for the Evaluation of the Clinical Outcome, Oxidation Profile and Wear Analysis of Medium Cross-linked Polyethylene With and Without Vitamin E for Total Knee Arthroplasty [NCT04618016]560 participants (Anticipated)Observational2021-03-08Recruiting
A Randomized Study to Compare the Efficacy of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Patients With Non-alcoholic Fatty Liver Disease Using (IL6 and CCL2) as a Predictors of Non-alcoholic Steatohepatitis [NCT04977661]Phase 4102 participants (Actual)Interventional2020-02-01Completed
Phase 1a: A Randomized, 2-period Cross-over Study to Compare the Bioavailability of Gamma-Delta Tocotrienol (GDT) With That of Tocotrienol Rich Fraction (TRF) in Twelve Healthy Subjects [NCT01571921]Phase 112 participants (Actual)Interventional2013-01-31Completed
Effect of Stellate Ganglion Block on Meniere's Disease [NCT01574313]Phase 420 participants (Actual)Interventional2010-04-30Completed
Human Blood Outcomes Following Tocotrienol Supplementation - NUTRITION Phase I and Phase IIA [NCT01578629]Phase 1/Phase 2210 participants (Actual)Interventional2012-03-31Completed
Efficacy Of Tocotrienol a Natural Vitamin E In Biopsy Wound. [NCT01579227]101 participants (Anticipated)Observational2012-01-31Active, not recruiting
[NCT01594346]Phase 3349 participants (Actual)Interventional2000-09-30Completed
Effects of Antioxidants Supplementation on Muscular Function of Patients Affected by Facioscapulohumeral Dystrophy (FSHD) [NCT01596803]54 participants (Actual)Interventional2010-05-01Completed
Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients [NCT01597765]60 participants (Actual)Interventional2009-06-30Completed
A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating The Safety And Efficacy Of An Oral Supplement Containing Astaxanthin (2 mg) + Lycopene (1.8 mg) + D-Alpha-Tocopherol (10 IU) For The Treatment Of Skin Aging [NCT03460860]100 participants (Actual)Interventional2018-03-05Completed
Effectiveness of Vitamin E and Molecular Hydrogen-Rich Water on Radiation Therapy-Induced Adverse In Adult Patients With Rectal Carcinoma in Al-Quds, Palestine [NCT04713332]Phase 360 participants (Anticipated)Interventional2019-07-06Recruiting
A Randomised Double-blinded Placebo Controlled Study on the Effect of Topical Palm Tocotrienol on Skin Biophysical Properties [NCT05787743]41 participants (Actual)Interventional2023-07-17Terminated(stopped due to Sponsor withdrawal)
Therapeutic Effect of Semaglutide on Nonalcoholic Fatty Liver Disease in Obesity and/or Type 2 Diabetes Mellitus [NCT05813249]Phase 4180 participants (Anticipated)Interventional2023-02-15Recruiting
The Efficacy and Safety of Vitamin E Mixed Tocotrienols In Patients With Amyotrophic Lateral Sclerosis (ALS) : A Pilot Exploratory Study [NCT04140136]Phase 220 participants (Anticipated)Interventional2019-06-17Recruiting
Provision of Antioxidant Therapy in Hemodialysis (PATH) Study [NCT00237718]Phase 2385 participants (Actual)Interventional2006-04-30Completed
Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E [NCT01792115]Phase 222 participants (Actual)Interventional2013-05-01Completed
Evaluation of Lacrimal Punctal Changes by Anterior Segment Optical Coherence Tomography AS-OCT After Topical Combined Antibiotics and Steroids Treatment in Cases of Inflammatory Punctual Stenosis [NCT05028907]Phase 464 participants (Actual)Interventional2020-11-15Completed
Why Antiprogestrone (Mifepristone) and Cyp 26 Inhibitor Must be Combined With Tamoxifen or ( Tamoxifen and Retinoic Acid) for Treating Early Breast Cancer [NCT05016349]Phase 3160 participants (Anticipated)Interventional2021-08-31Not yet recruiting
Lipid Peroxidation and Options Antioxidant Therapy for Secondary Lymphedema of the Lower Extremities [NCT04360889]Phase 4120 participants (Actual)Interventional2019-09-01Completed
Oxidant Stress and Allergic Asthma [NCT00581048]33 participants (Actual)Interventional2006-12-31Completed
Effects of Vitamin E (Alfa-Tocoferol) Supplementation on Isoprostane and Lipid Profile of Obese Adolescent in Jakarta, Indonesia [NCT03358524]Phase 469 participants (Actual)Interventional2017-09-28Completed
Antioxidants Vitamins and Muscle Damage [NCT05127928]18 participants (Actual)Interventional2022-02-10Completed
Preventive Strategies in Colorectal Carcinogenesis Production and Meat Processing [NCT02473302]24 participants (Actual)Interventional2014-04-30Completed
Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma [NCT01897792]Phase 211 participants (Actual)Interventional2013-05-31Terminated(stopped due to Inability to recruit patients that meet inclusion criteria.)
Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women [NCT00862433]Phase 150 participants (Actual)Interventional2014-10-10Completed
Safety of Tocotrienols in Atrial Fibrillation After Coronary Artery Bypass Grafting Surgery: A Randomized Controlled Exploratory Trial [NCT03807037]Phase 2/Phase 3250 participants (Actual)Interventional2018-12-17Completed
The Effect of Vitamin C and E Therapy on Restless Leg Syndrome in Patients With End Stage Renal Disease on Haemodialysis [NCT05350124]Phase 3160 participants (Anticipated)Interventional2022-11-30Not yet recruiting
the Role of Vitamin E in Reducing Incidence of Dry Socket in Female Patients. A Randomized Clinical Trial [NCT05984173]Phase 440 participants (Actual)Interventional2022-01-01Completed
An Examination Into the Effects of a Nutraceutical Supplement on Cognition, Stress, and Eye and Skin Health in Adults With Self-reported Cognitive Complaints: a Randomised, Double-blind, Placebo-controlled Trial [NCT05941949]110 participants (Anticipated)Interventional2023-07-05Recruiting
Efficacy of Vitamin E in Hyperinsulinism/Hyperammonemia Syndrome [NCT04984798]Phase 20 participants (Actual)Interventional2022-11-30Withdrawn(stopped due to No study activity took place. The IND was withdrawn with the FDA by the Sponsor Investigator because of insurmountable hurdles in moving proposed research forward)
Faecal Microbiome as Determinant of the Effect of Diet on Colorectal-cancer Risk: Comparison of Meat Based Versus Pesco-vegetarian Diets (MeaTIc) [NCT03416777]103 participants (Actual)Interventional2019-06-01Completed
Efficacy of Natural Vitamin E Tocotrienol on the Treatment of Surgical Scars [NCT00700791]Early Phase 1168 participants (Anticipated)Interventional2008-07-31Terminated(stopped due to The PI moved to another Institution)
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS [NCT02104505]Phase 1/Phase 223 participants (Actual)Interventional2015-11-30Completed
Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer. A Randomized Phase II Marker Trial [NCT04245865]Phase 274 participants (Anticipated)Interventional2020-06-26Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00006392 (6) [back to overview]Number of Participants With Any Diagnosis of Cancer
NCT00006392 (6) [back to overview]Number of Participants With Colorectal Cancer
NCT00006392 (6) [back to overview]Number of Participants With Lung Cancer
NCT00006392 (6) [back to overview]Number of Participants With Prostate Cancer
NCT00006392 (6) [back to overview]Number of Participants With Serious Cardiovascular Events
NCT00006392 (6) [back to overview]Prostate Cancer Free Survival; Lung Cancer-free Survival, Colorectal Cancer-free Survival, Cancer-free Survival, Overall Survival
NCT00096356 (3) [back to overview]Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization
NCT00096356 (3) [back to overview]Effects of Coenzyme Q10 on Depression (as Measured by CES-D Short-form) 24 Weeks Following Randomization
NCT00096356 (3) [back to overview]Effects of Coenzyme Q10 on Quality of Life (as Measured by FACT-B) 24 Weeks Following Randomization
NCT00235716 (7) [back to overview]All-cause Mortality
NCT00235716 (7) [back to overview]Mini-Mental State Examination Change From Baseline
NCT00235716 (7) [back to overview]Caregiver Activity Survey Change From Baseline
NCT00235716 (7) [back to overview]Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL) Inventory Change From Baseline
NCT00235716 (7) [back to overview]Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Change From Baseline
NCT00235716 (7) [back to overview]Neuropsychiatric Inventory Change From Baseline
NCT00235716 (7) [back to overview]Dependence Scale: Time to Event Analysis (Increase of of One Dependence Level)
NCT00237718 (2) [back to overview]Interleukin-6 (IL-6)
NCT00237718 (2) [back to overview]F2-isoprostane (F2-iso)
NCT00581048 (2) [back to overview]Allergen-provoked Concentrations of Immunoglobulin E (IgE) in BAL
NCT00581048 (2) [back to overview]Allergen-provoked Concentrations of Th1 and Th2 Cytokines in BAL
NCT00678834 (1) [back to overview]"The Levels of TCT in the Tissues of Non-healthy Subjects and in the Tissue of Healthy Subjects Following Oral Supplementation (200 mg x 2 Per Day for 4-24 Weeks)"
NCT00706121 (9) [back to overview]Effect Modification of Vitamin E by Body Mass Index on CRA Occurence, Analyzed by Active Vitamin e vs. Vitamin e Placebo
NCT00706121 (9) [back to overview]Effect Modification of Vitamin E by Aspirin on CRA Occurrence, Analyzed by Active Vitamin e vs. Vitamin e Placebo
NCT00706121 (9) [back to overview]Effect Modification of Selenium by Body Mass Index on CRA Occurrence, Analyzed by Active Selenium vs. Selenium Placebo
NCT00706121 (9) [back to overview]Effect Modification of Selenium by Aspirin on CRA Occurrence, Analyzed by Active Selenium vs. Selenium Placebo
NCT00706121 (9) [back to overview]Effect of Vitamin E on CRA Occurrence, Analyzed by Active Vitamin E vs. Vitamin E Placebo
NCT00706121 (9) [back to overview]Effect of Selenium on Occurrences of Multiple (>2) Adenomas
NCT00706121 (9) [back to overview]Effect of Selenium on Colorectal Adenoma (CRA) Occurrence, Analyzed by Active Selenium vs. Selenium Placebo
NCT00706121 (9) [back to overview]Effect of Selenium on Advanced Neoplasia, Analyzed by Active Selenium vs. Selenium Placebo
NCT00706121 (9) [back to overview]Effect of Selenium and/or Vitamin E on Colorectal Cancer (CRC) Incidence
NCT00740714 (23) [back to overview]Adverse Experiences: Depression
NCT00740714 (23) [back to overview]Adverse Experiences: Headache
NCT00740714 (23) [back to overview]Adverse Experiences: Hypertension
NCT00740714 (23) [back to overview]Adverse Experiences: Insomnia
NCT00740714 (23) [back to overview]Adverse Experiences: Insomnia: Moderate/Severe
NCT00740714 (23) [back to overview]Adverse Experiences: Nasopharyngitis
NCT00740714 (23) [back to overview]Adverse Experiences: Nausea
NCT00740714 (23) [back to overview]Adverse Experiences: Tremor
NCT00740714 (23) [back to overview]Adverse Experiences: Urinary Tract Infection
NCT00740714 (23) [back to overview]Change in Hoehn & Yahr Score From Baseline to 16 Months
NCT00740714 (23) [back to overview]CoQ10 Levels in Plasma
NCT00740714 (23) [back to overview]Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Total Score (Sum of Parts I, II and III Ranges From 0 to 176))
NCT00740714 (23) [back to overview]Change in Symbol Digit Modalities Test From Baseline to 16 Months
NCT00740714 (23) [back to overview]Change in PD Quality of Life Scale From Baseline to 16 Months
NCT00740714 (23) [back to overview]Change in Modified Schwab & England Independence Scale From Baseline to 16 Months
NCT00740714 (23) [back to overview]Adverse Experiences: Diarrhoea
NCT00740714 (23) [back to overview]Change in Modified Rankin Scale From Baseline to 16 Months
NCT00740714 (23) [back to overview]Adverse Experiences: Anxiety
NCT00740714 (23) [back to overview]Adverse Experiences: Anxiety: Moderate/Severe
NCT00740714 (23) [back to overview]Adverse Experiences: Back Pain
NCT00740714 (23) [back to overview]Adverse Experiences: Back Pain: Moderate/Severe
NCT00740714 (23) [back to overview]Adverse Experiences: Constipation
NCT00740714 (23) [back to overview]Adverse Experiences: Constipation: Moderate/Severe
NCT01002547 (17) [back to overview]Triglycerides
NCT01002547 (17) [back to overview]Number of Participants With Resolution of NASH Without Worsening of Fibrosis
NCT01002547 (17) [back to overview]Plasma ALT
NCT01002547 (17) [back to overview]Body Mass Index
NCT01002547 (17) [back to overview]Plasma AST
NCT01002547 (17) [back to overview]Total Body Fat by DEXA
NCT01002547 (17) [back to overview]Individual Histological Scores
NCT01002547 (17) [back to overview]Total Cholesterol
NCT01002547 (17) [back to overview]Liver Fat by Magnetic Resonance Imaging and Spectroscopy (MRS).
NCT01002547 (17) [back to overview]Liver Histology (Kleiner's et al Criteria, Hepatology 2005)
NCT01002547 (17) [back to overview]Matsuda Index
NCT01002547 (17) [back to overview]Weight
NCT01002547 (17) [back to overview]Fasting Plasma Insulin
NCT01002547 (17) [back to overview]Mean Individual Histological Scores
NCT01002547 (17) [back to overview]HDL-cholesterol
NCT01002547 (17) [back to overview]LDL-cholesterol
NCT01002547 (17) [back to overview]Fasting Plasma Glucose
NCT01314443 (3) [back to overview]Absolute Change From Baseline in Plasma Gamma-tocopherol (Vitamin E) at Day 7 From Day 0.
NCT01314443 (3) [back to overview]Absolute Change From Baseline in Plasma Malondialdehyde at Day 7 From Day 0.
NCT01314443 (3) [back to overview]Absolute Change in Brachial Artery Flow-mediated Dilation at Day 7 From Day 0
NCT01792115 (8) [back to overview]Biochemical: Number of Patients With Normal Transaminases at End of Treatment.
NCT01792115 (8) [back to overview]Absolute Change in GGT
NCT01792115 (8) [back to overview]Absolute Change in AST
NCT01792115 (8) [back to overview]Absolute Change in ALT
NCT01792115 (8) [back to overview]Percent Change in ALT
NCT01792115 (8) [back to overview]Physiological: Absolute Change in Liver Fat
NCT01792115 (8) [back to overview]Percent Change in Liver Fat
NCT01792115 (8) [back to overview]Percent Change in AST
NCT01897792 (10) [back to overview]Mean Number of Days in ICU.
NCT01897792 (10) [back to overview]Mean Number of Hospital Stay Days.
NCT01897792 (10) [back to overview]Mean Number of Ventilator-free Days for Subjects
NCT01897792 (10) [back to overview]Number of Participants With Coagulation Abnormalities
NCT01897792 (10) [back to overview]Number of Protocol Violations Per Arm.
NCT01897792 (10) [back to overview]Number of Subjects Surviving to Day 28
NCT01897792 (10) [back to overview]Number of Subjects With 60-day Survival
NCT01897792 (10) [back to overview]Number of Subjects With Organ Injury
NCT01897792 (10) [back to overview]Number of Subjects With Ventilator-associated Pneumonia.
NCT01897792 (10) [back to overview]Number of Total Blood Product Transfusions
NCT02104505 (4) [back to overview]Mucociliary Clearance as Affected by Gamma Tocopherol
NCT02104505 (4) [back to overview]Chronic Eosinophilic Airway Inflammation as Affected by Gamma Tocopherol
NCT02104505 (4) [back to overview]Comparison of Change in Sputum Percent Neutrophils (PMN)s Following Inhaled Clinical Center Reference Endotoxin (CCRE) Challenge as Affected by Gamma Tocopherol
NCT02104505 (4) [back to overview]Mucociliary Clearance (MCC) Associated With CCRE Challenge as Affected by Gamma Tocopherol
NCT02368457 (2) [back to overview]Clinical Symptoms Evaluation, Measured Using the LENT-SOMA Scale
NCT02368457 (2) [back to overview]Bone and/or Tissue Healing as Measured With the Classification of ORN Stages, Area of Bone Exposed (mm2) and Radiological Findings (OPG).
NCT02911688 (8) [back to overview]Change in Sputum IL-8 From Baseline Following Ozone Exposure
NCT02911688 (8) [back to overview]Change in Sputum IL-6 From Baseline Following Ozone Exposure
NCT02911688 (8) [back to overview]Change in Central Lung Clearance of Technetium Sulfur Colloid Particles (0-30 Minutes) From Baseline Following Ozone Exposure
NCT02911688 (8) [back to overview]Change From Baseline in Sputum Percent Neutrophils (%PMN) Following Ozone Exposure
NCT02911688 (8) [back to overview]Change in Whole Lung Clearance of Technetium Sulfur Colloid Particles (0-120 Minutes) From Baseline Following Ozone Exposure
NCT02911688 (8) [back to overview]Change in Sputum Tumor Necrosis Factor (TNF)-Alpha From Baseline Following Ozone Exposure
NCT02911688 (8) [back to overview]Change in Sputum Percent Eosinophils From Baseline Following Ozone Exposure
NCT02911688 (8) [back to overview]Change in Sputum Interleukin (IL)-1b From Baseline Following Ozone Exposure
NCT03797222 (11) [back to overview]Delta-plasma Ammonia Concentration
NCT03797222 (11) [back to overview]Delta-plasma Glucose Concentration
NCT03797222 (11) [back to overview]Delta-plasma Insulin Concentration
NCT03797222 (11) [back to overview]Fasting Plasma Ammonia Concentration
NCT03797222 (11) [back to overview]Fasting Plasma Glucose Concentration
NCT03797222 (11) [back to overview]Hypoglycemia Frequency
NCT03797222 (11) [back to overview]Nadir Plasma Glucose Concentration
NCT03797222 (11) [back to overview]Peak Plasma Insulin Concentration
NCT03797222 (11) [back to overview]Plasma Alpha-tocopherol Concentration
NCT03797222 (11) [back to overview]Tolerability of Vitamin E Based on Responses to a Subject/Parent-reported Symptom Questionnaire After Vitamin E Supplementation Compared to Baseline
NCT03797222 (11) [back to overview]Fasting Plasma Insulin Concentration
NCT03830164 (3) [back to overview]Choosing Other Erectile Dysfunction (ED) Treatments After Pentoxifylline, Atorvastatin and Vitamin E (PAVE)
NCT03830164 (3) [back to overview]Change in International Index of Erectile Function (IIEF) Scores
NCT03830164 (3) [back to overview]Number of Participants With Incidence of Adverse Events (AEs)
NCT04134091 (13) [back to overview]Number of Subjects With an Improvement in Liver Fibrosis Greater Than or Equal to One Stage and no Worsening of NASH in LPCN 1144 Treated Subjects Compared to Placebo.
NCT04134091 (13) [back to overview]Number of Subjects Achieving Resolution of NASH on Overall Histopathological Reading and no Worsening of Liver Fibrosis in LPCN 1144 Treated Subjects Compared to Placebo.
NCT04134091 (13) [back to overview]Number of Participants With Resolution of NASH on Overall Histopathological Reading in LPCN 1144 Treated Subjects Compared to Placebo
NCT04134091 (13) [back to overview]Absolute Change in Hepatic Fat Fraction Based on MRI-PDFF Measurements in LPCN 1144 Treated Subjects Compared to Placebo.
NCT04134091 (13) [back to overview]Mean Changes in Serum Lipid Profile Parameters in LPCN 1144 Treated Subjects Compared to Placebo.
NCT04134091 (13) [back to overview]Mean Change From Baseline in Liver Enzymes in LPCN 1144 Treated Subjects Compared to Placebo.
NCT04134091 (13) [back to overview]Change in the Mean Score of NAS Components at Baseline and After 36 Weeks of Treatment in LPCN 1144 Treated Subjects Compared to Placebo.
NCT04134091 (13) [back to overview]Relative Change in Whole Body Fat Mass
NCT04134091 (13) [back to overview]Relative Change in MRI-PDFF Measurements in LPCN 1144 Treated Subjects Compared to Placebo.
NCT04134091 (13) [back to overview]Relative Change in Appendicular Lean Muscle Mass
NCT04134091 (13) [back to overview]Number of Subjects With Improvement in NASH Evaluated by Paired Biopsies Analysis and no Worsening of Liver Fibrosis in LPCN 1144 Treated Subjects Compared to Placebo.
NCT04134091 (13) [back to overview]Number of Subjects With Improvement in Fibrosis Evaluated Via FibroNest Scores
NCT04134091 (13) [back to overview]Number of Subjects With Improvement in Fibrosis Evaluated by Paired Biopsies Analysis and no Worsening of NASH in LPCN 1144 Treated Subjects Compared to Placebo
NCT04198805 (24) [back to overview]Change in Fibrosis-4 (FIB-4) Score
NCT04198805 (24) [back to overview]Change in Hepatic Fat Fraction [%] Between DHA EE vs Placebo Arm
NCT04198805 (24) [back to overview]Change in Hepatic Fat Fraction [%] Between of Vitamin E and DHA EE vs Placebo
NCT04198805 (24) [back to overview]Change in Hepatic Fat Fraction [%] Between Vitamin E vs Placebo Arm
NCT04198805 (24) [back to overview]Liver Enzymes Alkaline Phosphatase in the DHA EE and /or Vitamin E Intervention Over a 6 Month Period.
NCT04198805 (24) [back to overview]Change in Health Related Quality of Life Score (Short Form (SF-36))
NCT04198805 (24) [back to overview]Change in Plasma Vitamin E Concentration
NCT04198805 (24) [back to overview]Change in Plasma DHA EE Concentration
NCT04198805 (24) [back to overview]Change in Liver Enzymes Bilirubin in the DHA EE and /or Vitamin E Intervention Over a 6 Month Period.
NCT04198805 (24) [back to overview]Change in Liver Enzymes (AST) in the DHA EE and /or Vitamin E Intervention Over a 6 Month Period.
NCT04198805 (24) [back to overview]Change in Liver Enzymes (ALT) in the DHA EE and /or Vitamin E Intervention Over a 6 Month Period.
NCT04198805 (24) [back to overview]Change in Lipid Profile (Triglycerides)
NCT04198805 (24) [back to overview]Change in Dietary Intake Levels of Long-chain Polyunsaturated Fatty Acids (LC-PUFA ) (i.e. DHA and EPA) as Measured by the Food Frequency Questionnaire (FFQ)
NCT04198805 (24) [back to overview]Change in Lipid Profile (Oxidized LDL)
NCT04198805 (24) [back to overview]Change in Lipid Profile (Low Density Lipoprotein (LDL-C))
NCT04198805 (24) [back to overview]Change in Lipid Profile (HDL-C)
NCT04198805 (24) [back to overview]Change in Insulin Levels to Determine Insulin Resistance
NCT04198805 (24) [back to overview]Change in Inflammatory Markers (TNFα)
NCT04198805 (24) [back to overview]Change in Inflammatory Markers (IL-1β)
NCT04198805 (24) [back to overview]Change After 6 Months of DHA EE and /or Vitamin E Intervention in the Anthropometric Measure, Bodyweight.
NCT04198805 (24) [back to overview]Change After 6 Months of DHA EE and/ or Vitamin E Intervention in the Anthropometric Measure, Body Mass Index (BMI)
NCT04198805 (24) [back to overview]Change After 6 Months of DHA EE and/ or Vitamin E Intervention in the Anthropometric Measure, Waist Circumference.
NCT04198805 (24) [back to overview]Change After 6 Months of DHA EE and/ or Vitamin E Intervention in the Anthropometric Measure, Waist-to-hip Ratio .
NCT04198805 (24) [back to overview]Change in Inflammatory Markers (Cytokeratin 18 (CK-18))

Number of Participants With Any Diagnosis of Cancer

Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized. (NCT00006392)
Timeframe: Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.

Interventionparticipants (Number)
Vitamin E856
Selenium837
Combination846
Placebo824

[back to top]

Number of Participants With Colorectal Cancer

Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized. (NCT00006392)
Timeframe: Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.

Interventionparticipants (Number)
Vitamin E66
Selenium63
Combination77
Placebo60

[back to top]

Number of Participants With Lung Cancer

Participants are seen at the study site every six month for an update of medical events. Cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Follow-up was planned for seven to 12 years depending on when the participant was randomized. (NCT00006392)
Timeframe: Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.

Interventionparticipants (Number)
Vitamin E67
Selenium75
Combination78
Placebo67

[back to top]

Number of Participants With Prostate Cancer

Participants are seen at the study site every six month for an update of medical events. Prostate cancer diagnosis is based on participant report followed by the submission of a pathologic sample to central pathology review for confirmation. (NCT00006392)
Timeframe: Every six months for 7 to 12 years depending on when the participant was randomized.

Interventionparticipants (Number)
Vitamin E473
Selenium432
Combination437
Placebo416

[back to top]

Number of Participants With Serious Cardiovascular Events

Participants are seen at the study site every six month for an update of medical events. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Cardiovascular events are based on self-report and are not confirmed. Follow-up was planned for seven to 12 years depending on when the participant was randomized. (NCT00006392)
Timeframe: Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.

Interventionparticipants (Number)
Vitamin E1034
Selenium1080
Combination1041
Placebo1050

[back to top]

Prostate Cancer Free Survival; Lung Cancer-free Survival, Colorectal Cancer-free Survival, Cancer-free Survival, Overall Survival

Participants are seen at the study site every six month for an update of medical events. If the participant has been diagnosed with prostate cancer, study site visits are once a year. Prostate cancer diagnosis is based on participant report followed by the submission of a pathologic sample to central pathology review for confirmation. Other cancer diagnoses are based on participant report. Medical records for non-prostate cancers were collected but they were not pathologically confirmed. Follow-up was planned for seven to 12 years depending on when the participant was randomized. (NCT00006392)
Timeframe: Participants are assessed for medical every six months for 7 to 12 years depending on when he was randomized . Upon diagnosis of prostate cancer, updates are annual.

,,,
Interventionparticipants (Number)
All deathsAll cancer deathsProstate cancer deathsLung cancer deathsColorectal cancer deaths
Combination35911703915
Placebo38212504110
Selenium37812814510
Vitamin E35810603813

[back to top]

Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization

POMS-F is the Profile of Mood States - fatigue scale. It ranges from 0 to 28; higher values indicate greater fatigue. (NCT00096356)
Timeframe: 24 weeks

Interventionunits on a scale (Least Squares Mean)
Arm 1 - CoQ10 & Vitamin E6.96
Arm 2 - Placebo & Vitamin E8.33

[back to top]

Effects of Coenzyme Q10 on Depression (as Measured by CES-D Short-form) 24 Weeks Following Randomization

CES-D is the Center for Epidemiologic Studies Depression Form. It consists of 20 questions. The total score ranges from 0 to 60. Higher scores indicate greater depression. (NCT00096356)
Timeframe: 24 weeks

Interventionunits on a scale (Least Squares Mean)
Arm 1- CoQ10 & Vitamin E11.7
Arm 2 - Placebo & Vitamin E12.4

[back to top]

Effects of Coenzyme Q10 on Quality of Life (as Measured by FACT-B) 24 Weeks Following Randomization

FACT-B stands for Functional Assessment of Cancer Therapy - Breast. It measures quality of life. It is the total of the FACT subscales (emotional, social, functional, and physical) and the Breast subscale. Scores range from 0 to 144; higher scores reflect better overall quality of life. (NCT00096356)
Timeframe: 24 weeks

Interventionunits on a scale (Least Squares Mean)
Arm 1 - CoQ10 & Vitamin E111.8
Arm 2 - Placebo & Vitamin E109.8

[back to top]

All-cause Mortality

Survival analysis of death from any cause. (NCT00235716)
Timeframe: up to 4 years

Interventionparticipants (Number)
Vitamin E26
Memantine39
Vitamin E + Memantine32
Placebo31

[back to top]

Mini-Mental State Examination Change From Baseline

The Mini-Mental State Examination (MMSE) briefly and objectively assess cognitive status in psychiatric patients with cognitive impairment. The MMSE questions are grouped into seven categories, each representing a different cognitive domain. The MMSE yields a total score that ranges from 0 for a patient who gives no correct response to a score of 30 for a patient who makes no errors. Outcome analysis is average least square means change from baseline. (NCT00235716)
Timeframe: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline

,,,
Interventionunits on a scale (Least Squares Mean)
6 months minus baseline12 months minus baseline18 months minus baseline24 months minus baseline30 months minus baseline36 months minus baseline42 months minus baseline48 months minus baselineAverage change from baseline
Memantine-0.24-1.09-2.62-3.44-3.79-4.26-4.59-5.98-3.05
Placebo-0.34-1.39-2.21-2.90-3.26-3.87-4.68-5.42-3.16
Vitamin E-0.35-0.95-2.00-2.62-3.67-4.97-4.84-5.26-2.97
Vitamin E + Memantine-0.20-0.65-1.22-2.29-3.16-3.69-3.80-5.70-2.80

[back to top]

Caregiver Activity Survey Change From Baseline

The Caregiver Activity Survey (CAS) was developed to measure the time caregivers spend aiding Alzheimer patients with their day-to-day activities. The CAS consists of six items that ask for an estimate in hours and minutes of the time that the caregiver spent during the previous 24 hours performing these particular activities. The six CAS items are as follows: 1) communication with the person, 2) using transportation, 3) dressing, 4) eating, 5) looking after one's appearance, and 6) supervising the person. The more caregiving hours the worse the patient's functioning level. Outcome analysis is average least square means change from baseline. (NCT00235716)
Timeframe: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline

,,,
Interventionhours per day (Least Squares Mean)
6 months minus baseline12 months minus baseline18 months minus baseline24 months minus baseline30 months minus baseline36 months minus baseline42 months minus baseline48 months minus baselineAverage change from baseline
Memantine0.992.723.773.065.225.729.469.275.52
Placebo1.201.893.163.454.3610.6810.6212.175.14
Vitamin E-0.93-0.182.121.604.147.694.9510.173.35
Vitamin E + Memantine1.081.392.692.823.414.905.4813.805.00

[back to top]

Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL) Inventory Change From Baseline

The primary outcome of the study was the Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL) Inventory. The ADCS/ADL Inventory is designed to assess functional abilities to perform activities of daily living in Alzheimer patients with a broad range of dementia severity. The total score ranges from 0 to 78 with higher scores indicating greater abilities. Outcome analysis is average least square means change from baseline. (NCT00235716)
Timeframe: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline

,,,
Interventionunits on a scale (Least Squares Mean)
6 months minus baseline12 months minus baseline18 months minus baseline24 months minus baseline30 months minus baseline36 months minus baseline42 months minus baseline48 months minus baselineAverage change from baseline
Memantine-2.40-6.99-9.32-14.06-18.30-18.78-23.48-24.60-14.98
Placebo-4.52-8.11-10.21-16.18-19.67-24.82-28.13-27.55-16.96
Vitamin E-1.72-4.29-8.01-11.88-15.84-19.71-25.30-26.55-13.81
Vitamin E + Memantine-2.78-6.60-7.98-12.82-15.66-18.89-23.44-29.25-15.20

[back to top]

Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Change From Baseline

The Alzheimer's Disease Assessment Scale (ADAS) is a 21-item scale designed to assess the severity of cognitive and non-cognitive behavioral impairments in patients with Alzheimer's disease. The cognitive portion of the scale (ADAS-cog) consists of 11 items to assess memory, language, and praxis functions. The ADAS-cog total score ranges from 0 (no errors) to 70 (severe cognitive impairment). Outcome analysis is average least square means change from baseline. (NCT00235716)
Timeframe: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline

,,,
Interventionunits on a scale (Least Squares Mean)
6 months minus baseline12 months minus baseline18 months minus baseline24 months minus baseline30 months minus baseline36 months minus baseline42 months minus baseline48 months minus baselineAverage change from baseline
Memantine1.113.325.696.737.648.318.2411.746.38
Placebo3.044.266.046.718.9010.7710.6110.857.78
Vitamin E1.382.404.344.327.879.0010.3510.735.97
Vitamin E + Memantine1.532.483.465.765.858.267.979.706.13

[back to top]

Neuropsychiatric Inventory Change From Baseline

The Neuropsychiatric Inventory (NPI) assesses psychological and behavioral problems in patients with dementia. For each of twelve domains, there are four scores: frequency, severity, total frequency x severity, and caregiver distress. The frequency x severity total scores from each domain are summed for an overall total score that ranges from 0 to 144. The total caregiver distress scores are also summed for an overall total caregiver distress score that ranges from 0 to 60. The secondary endpoint for the trial will be the overall frequency times severity total score. Outcome analysis is average least square means change from baseline. (NCT00235716)
Timeframe: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline

,,,
Interventionunits on a scale (Least Squares Mean)
6 months minus baseline12 months minus baseline18 months minus baseline24 months minus baseline30 months minus baseline36 months minus baseline42 months minus baseline48 months minus baselineAverage change from baseline
Memantine-0.200.311.184.292.623.243.632.791.87
Placebo0.461.084.063.591.660.603.640.302.26
Vitamin E-1.24-1.040.932.163.212.150.81-0.600.79
Vitamin E + Memantine-0.47-0.170.411.982.162.791.855.141.79

[back to top]

Dependence Scale: Time to Event Analysis (Increase of of One Dependence Level)

The Dependence Scale assesses the level of assistance needed by patients with Alzheimer's disease for activities of daily living. The scale yields six levels of dependence: no assistance required (Level 0); requires occasional reminders (Level 1); requires frequent reminders and/or help with household chores (Level 2); needs daily supervision (Level 3); needs to be dressed, toileted or fed (Level 4); needs to be transferred, diapered or tube fed (Level 5). (NCT00235716)
Timeframe: Every 6 months to a maximum of 4 years

Interventionparticipants (Number)
Vitamin E80
Memantine87
Vitamin E + Memantine87
Placebo79

[back to top]

Interleukin-6 (IL-6)

IL-6 is a sensitive laboratory assay for serum levels of interleukin-6, which is a pro-inflammatory cytokine used to evaluate the inflammatory response. (NCT00237718)
Timeframe: month 6

Interventionpg/ml (Mean)
ALA and Vitamin E19
Placebo20

[back to top]

F2-isoprostane (F2-iso)

F2-iso is a sensitive laboratory assay for serum levels of F2-isoprostane, which is a biomarker of oxidative stress. (NCT00237718)
Timeframe: month 6

Interventionng/ml (Mean)
ALA and Vitamin E0.077
Placebo0.073

[back to top]

Allergen-provoked Concentrations of Immunoglobulin E (IgE) in BAL

(NCT00581048)
Timeframe: baseline to after 16-18 weeks of treatment with vitamin E daily

InterventionUI/ml (Median)
Before Treatment, Baseline4.05
After Treatment3.65

[back to top]

Allergen-provoked Concentrations of Th1 and Th2 Cytokines in BAL

(NCT00581048)
Timeframe: baseline to after 16-18 weeks of treatment with vitamin E daily

,
Interventionpg/mL (Median)
IL-1BIL-2IL-3IL-4IL-5IL-6IL-9IL-10IL-12IL-13TNF-aINF-YCXCL8CCL5CCL11
After Treatment1.210.691.40.0450.81700.70.1651.03.020.753.22.32.70
Before Treatment, Baseline0.970.481.60.171.021.500.530.050.62.760.4944.03.01.0

[back to top]

"The Levels of TCT in the Tissues of Non-healthy Subjects and in the Tissue of Healthy Subjects Following Oral Supplementation (200 mg x 2 Per Day for 4-24 Weeks)"

(NCT00678834)
Timeframe: After at least 1 month of supplementation

Interventionnmol/g (Mean)
Arm 1: Surgical, Adipose9.94
Arm 1: Surgical, Brain1.29
Arm 1: Surgical, Heart5.37
Arm 1: Surgical, Liver0.42
Arm 2: Surgical, Adipose28.6
Arm 2: Surgical, Brain50.5
Arm 2: Surgical, Heart31.9
Arm 2: Surgical, Liver64.3
Arm 3: Healthy, Blood, Week 00.01
Arm 3: Healthy, Blood, Week 61.9
Arm 3: Healthy, Skin, Week 121.5
Arm 3: Healthy, Skin, Week 02.5
Arm 3: Healthy, Blood, Week 120.03

[back to top]

Effect Modification of Vitamin E by Body Mass Index on CRA Occurence, Analyzed by Active Vitamin e vs. Vitamin e Placebo

(NCT00706121)
Timeframe: From 1 year post randomization through study completion

,
Interventionercentage of participants in subgroup (Number)
NormalOverweightObese
Active Vitamin E30.236.836.5
Vitamin E Placebo31.434.935.7

[back to top]

Effect Modification of Vitamin E by Aspirin on CRA Occurrence, Analyzed by Active Vitamin e vs. Vitamin e Placebo

(NCT00706121)
Timeframe: From 1 year post randomization through study completion

,
Interventionercentage of participants in subgroup (Number)
UsersNon-users
Active Vitamin E34.536.5
Vitamin E Placebo35.333.3

[back to top]

Effect Modification of Selenium by Body Mass Index on CRA Occurrence, Analyzed by Active Selenium vs. Selenium Placebo

(NCT00706121)
Timeframe: From 1 year post randomization through study completion

,
Interventionpercentage of participants (Number)
NormalOverweightObese
Active Selenium30.235.235.2
Selenium Placebo31.436.537.0

[back to top]

Effect Modification of Selenium by Aspirin on CRA Occurrence, Analyzed by Active Selenium vs. Selenium Placebo

(NCT00706121)
Timeframe: From 1 year post randomization through study completion

,
Interventionercentage of participants in subgroup (Number)
UsersNon-users
Active Selenium33.534.9
Selenium Placebo36.434.9

[back to top]

Effect of Vitamin E on CRA Occurrence, Analyzed by Active Vitamin E vs. Vitamin E Placebo

(NCT00706121)
Timeframe: From 1 year post randomization through study completion

InterventionParticipants (Count of Participants)
Active Vitamin E1159
Vitamin E Placebo1127

[back to top]

Effect of Selenium on Occurrences of Multiple (>2) Adenomas

(NCT00706121)
Timeframe: From 1 year post randomization through study completion

InterventionParticipants (Count of Participants)
Active Selenium258
Selenium Placebo276

[back to top]

Effect of Selenium on Colorectal Adenoma (CRA) Occurrence, Analyzed by Active Selenium vs. Selenium Placebo

(NCT00706121)
Timeframe: From 1 year post randomization through study completion

InterventionParticipants (Count of Participants)
Active Selenium1136
Selenium Placebo1150

[back to top]

Effect of Selenium on Advanced Neoplasia, Analyzed by Active Selenium vs. Selenium Placebo

Adenomas with diameter >=1cm or any adenoma with villous features or high-grade dysplasia (NCT00706121)
Timeframe: From 1 year post randomization through study completion

InterventionParticipants (Count of Participants)
Active Selenium269
Selenium Placebo282

[back to top]

Effect of Selenium and/or Vitamin E on Colorectal Cancer (CRC) Incidence

(NCT00706121)
Timeframe: From 1 year post randomization through study completion

InterventionParticipants (Count of Participants)
Vitamin E10
Selenium11
Combination9
Placebo6

[back to top]

Adverse Experiences: Depression

Number of participants with depression (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day9
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day6
C. Placebo With Vitamin E 1200 IU/Day14

[back to top]

Adverse Experiences: Headache

Number of participants with headache (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day9
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day8
C. Placebo With Vitamin E 1200 IU/Day11

[back to top]

Adverse Experiences: Hypertension

Number of participants with hypertension (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day5
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day7
C. Placebo With Vitamin E 1200 IU/Day0

[back to top]

Adverse Experiences: Insomnia

Number of participants with insomnia (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day6
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day13
C. Placebo With Vitamin E 1200 IU/Day6

[back to top]

Adverse Experiences: Insomnia: Moderate/Severe

Number of participants with moderate/severe insomnia (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day2
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day9
C. Placebo With Vitamin E 1200 IU/Day0

[back to top]

Adverse Experiences: Nasopharyngitis

Number of participants with nasopharyngitis (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day7
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day9
C. Placebo With Vitamin E 1200 IU/Day3

[back to top]

Adverse Experiences: Nausea

Number of participants with nausea (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day7
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day7
C. Placebo With Vitamin E 1200 IU/Day10

[back to top]

Adverse Experiences: Tremor

Number of participants with tremor (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day10
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day13
C. Placebo With Vitamin E 1200 IU/Day8

[back to top]

Adverse Experiences: Urinary Tract Infection

Number of patients with urinary tract infections (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day6
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day8
C. Placebo With Vitamin E 1200 IU/Day3

[back to top]

Change in Hoehn & Yahr Score From Baseline to 16 Months

The Modified Hoehn and Yahr Scale is an 8-level Parkinson disease staging instrument. The investigator will assess disease stage at each level. The disease stages range from the best outcome of 0 (no signs of disease) to the worst outcome of 5 (wheelchair bound or bedridden unless aided). (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Interventionunits on a scale (Least Squares Mean)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day.21
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day.20
C. Placebo With Vitamin E 1200 IU/Day.16

[back to top]

CoQ10 Levels in Plasma

Based on samples analyzed to date (NCT00740714)
Timeframe: Baseline, 1, 8 and 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

,,
Interventionug/ml (Mean)
1 month visit8 month visit16 month visit
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day3.553.322.88
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day2.572.672.17
C. Placebo With Vitamin E 1200 IU/Day.751.07.63

[back to top]

Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Total Score (Sum of Parts I, II and III Ranges From 0 to 176))

Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 16 or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first. The UPDRS score has three components, each consisting of questions answered on a 0-4 point scale. Part I assesses mentation, behavior and mood; Part II assesses activities of daily living in the week prior to the designated visit; and Part III assesses motor abilities at the time of the visit. A total of 31 items are included in Parts I, II and III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score ranges from 0-176. (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Interventionunits on a scale (Least Squares Mean)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day8.01
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day7.50
C. Placebo With Vitamin E 1200 IU/Day6.92

[back to top]

Change in Symbol Digit Modalities Test From Baseline to 16 Months

The Symbol Digit Modalities Test screens cognitive impairment by using a simple substitution tasks that individuals with normal functioning can easily perform. The test score range is from 0(worst outcome) to 110 (best outcome). (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Interventionunits on a scale (Least Squares Mean)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day-3.36
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day-0.49
C. Placebo With Vitamin E 1200 IU/Day-3.02

[back to top]

Change in PD Quality of Life Scale From Baseline to 16 Months

The subject will complete a questionnaire that will evaluate how Parkinson disease has affected their health and overall quality of life at each visit. The total quality of life scale measures a total of 33 aspects of quality of life. Each aspect is rated on scale of 0 (best outcome) to 4 (worst outcome). Total score range is 0-132. A higher score or increased score compared to a previous visit indicates a lowered quality of life. (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Interventionunits on a scale (Least Squares Mean)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day5.06
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day6.12
C. Placebo With Vitamin E 1200 IU/Day5.57

[back to top]

Change in Modified Schwab & England Independence Scale From Baseline to 16 Months

This scale measures activities of daily living. This is an investigator and subject assessment of the subject's level of independence at all scheduled visits. The subject is scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to pre-Parkinson disease ability. Scores range in increments of 10%: 100% for normal (subject is completely independent; essentially normal) to 0% (vegetative functions such as swallowing, bladder and bowel functions are not functioning; bedridden). (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Interventionunits on a scale (Least Squares Mean)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day-4.94
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day-4.29
C. Placebo With Vitamin E 1200 IU/Day-4.07

[back to top]

Adverse Experiences: Diarrhoea

Number of participants with diarrhoea (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day6
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day9
C. Placebo With Vitamin E 1200 IU/Day11

[back to top]

Change in Modified Rankin Scale From Baseline to 16 Months

The Modified Rankin Scale is a global functional health index with a strong accent on physical disability. Subjects are scored on a scale of 0 (no symptoms at all) to 5 (severe disability: bedridden incontinent, and requiring constant nursing care and attention. (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Interventionunits on a scale (Least Squares Mean)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day.38
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day.31
C. Placebo With Vitamin E 1200 IU/Day.40

[back to top]

Adverse Experiences: Anxiety

Number of participants with anxiety (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day12
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day13
C. Placebo With Vitamin E 1200 IU/Day14

[back to top]

Adverse Experiences: Anxiety: Moderate/Severe

Number of participants with moderate/severe anxiety (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day9
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day9
C. Placebo With Vitamin E 1200 IU/Day7

[back to top]

Adverse Experiences: Back Pain

Number of participants with back pain (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day9
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day13
C. Placebo With Vitamin E 1200 IU/Day9

[back to top]

Adverse Experiences: Back Pain: Moderate/Severe

Number of participants with moderate/severe back pain (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day7
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day9
C. Placebo With Vitamin E 1200 IU/Day7

[back to top]

Adverse Experiences: Constipation

Number of participants with constipation (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day7
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day13
C. Placebo With Vitamin E 1200 IU/Day7

[back to top]

Adverse Experiences: Constipation: Moderate/Severe

Number of participants with moderate/severe constipation (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day3
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day10
C. Placebo With Vitamin E 1200 IU/Day3

[back to top]

Triglycerides

Change from baseline in plasma triglycerides after 18 months of therapy (NCT01002547)
Timeframe: Month 18

Interventionmg/dl (Median)
Placebo13
Vitamin E14
Pioglitazone + Vitamin E-2

[back to top]

Number of Participants With Resolution of NASH Without Worsening of Fibrosis

Resolution of NASH was defined as absence of NASH after 18 months of therapy in patients with definite NASH (presence of zone 3 accentuation of macrovesicular steatosis of any grade, hepatocellular ballooning of any degree, and lobular inflammatory infiltrates of any amount) at baseline. (NCT01002547)
Timeframe: Month 18

InterventionParticipants (Count of Participants)
Placebo5
Vitamin E14
Pioglitazone + Vitamin E20

[back to top]

Plasma ALT

Change from baseline in plasma ALT after 18 months of therapy (NCT01002547)
Timeframe: Month 18

InterventionU/L (Mean)
Placebo-6
Vitamin E-24
Pioglitazone + Vitamin E-18

[back to top]

Body Mass Index

Weight (in kg) / (Height [in m] x Height [in m]) (NCT01002547)
Timeframe: Month 18

Interventionkg/m2 (Mean)
Placebo-0.6
Vitamin E0.1
Pioglitazone + Vitamin E1.4

[back to top]

Plasma AST

Change from baseline in plasma AST after 18 months of therapy (NCT01002547)
Timeframe: Month 18

InterventionU/L (Mean)
Placebo-8
Vitamin E-15
Pioglitazone + Vitamin E-10

[back to top]

Total Body Fat by DEXA

Change from baseline in total body fat by DEX after 18 months of therapy (NCT01002547)
Timeframe: Month 18

Interventionpercentage (Mean)
Placebo0
Vitamin E0
Pioglitazone + Vitamin E2

[back to top]

Individual Histological Scores

"Number of patients with improvement of at least 1 grade in each of the histological parameters.~Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x.~Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning.~Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis." (NCT01002547)
Timeframe: Month 18

,,
InterventionParticipants (Count of Participants)
SteatosisInflammationBallooningFibrosis
Pioglitazone + Vitamin E32252319
Placebo15141110
Vitamin E24131819

[back to top]

Total Cholesterol

Change from baseline in plasma total cholesterol after 18 months of therapy (NCT01002547)
Timeframe: Month 18

Interventionmg/dl (Mean)
Placebo-11
Vitamin E5
Pioglitazone + Vitamin E1

[back to top]

Liver Fat by Magnetic Resonance Imaging and Spectroscopy (MRS).

Change from baseline in intrahepatic triglyceride content after 18 months of therapy (NCT01002547)
Timeframe: Month 18

Interventionpercentage (Mean)
Placebo1
Vitamin E-6
Pioglitazone + Vitamin E-10

[back to top]

Liver Histology (Kleiner's et al Criteria, Hepatology 2005)

"Number of patients with reduction of at least 2 points in the nonalcoholic fatty liver disease activity score (NAS) (with reduction in at least 2 different histological categories) without worsening of fibrosis. NAS is the sum of the separate scores for steatosis (0-3), hepatocellular ballooning (0-2) and lobular inflammation (0-3), and ranges from 0-8 .~The scoring system is based on the following grading:~Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis." (NCT01002547)
Timeframe: 18 months

InterventionParticipants (Count of Participants)
Placebo7
Vitamin E13
Pioglitazone + Vitamin E24

[back to top]

Matsuda Index

This is a method for assessing insulin resistance (IR) based on measurements of glucose and insulin during the oral glucose tolerance test. The formula used is = (10000/(SQRT(fasting plasma glucose * fasting plasma insulin * ((fasting plasma glucose * 15 + glucose at minute 30 * 30 + glucose at minute 60 * 30 + glucose at minute 90 * 30 + glucose at minute 120 * 15)/120)*((fasting plasma insulin * 15 + insulin at minute 30 * 30 + insulin at minute 60 * 30 + insulin at minute 90 * 30 + insulin at minute 120 * 15)/120))), with a lower value representing worse insulin resistance. (NCT01002547)
Timeframe: Month 18

Interventionunits on a scale (Mean)
Placebo2.53
Vitamin E2.31
Pioglitazone + Vitamin E4.02

[back to top]

Weight

Change from baseline in weight (NCT01002547)
Timeframe: Month 18

Interventionkg (Mean)
Placebo-0.8
Vitamin E0.5
Pioglitazone + Vitamin E5.7

[back to top]

Fasting Plasma Insulin

Change from baseline after 18 months of therapy (NCT01002547)
Timeframe: Month 18

InterventionuU/ml (Mean)
Placebo3
Vitamin E-3
Pioglitazone + Vitamin E-3

[back to top]

Mean Individual Histological Scores

"Mean change in individual scores compared to baseline. Steatosis range 0-3, where: 0 = <5% fat; 1 = 5-33% fat; 2 = >33-66% fat; 3 = >66% fat.~Lobular Inflammation, range 0-3, where: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x.~Hepatocyte Ballooning, range 0-2, where: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning.~Fibrosis stage, range 0-4, where: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis." (NCT01002547)
Timeframe: Month 18

,,
Interventionunits on a scale (Mean)
SteatosisInflammationBallooningFibrosis
Pioglitazone + Vitamin E-1.3-0.6-0.6-0.6
Placebo-0.4-0.2-0.1-0.3
Vitamin E-1.0-0.4-0.5-0.6

[back to top]

HDL-cholesterol

Change from baseline in plasma HDL-cholesterol after 18 months of therapy (NCT01002547)
Timeframe: Month 18

Interventionmg/dl (Mean)
Placebo-1
Vitamin E1
Pioglitazone + Vitamin E3

[back to top]

LDL-cholesterol

Change from baseline in plasma LDL-cholesterol after 18 months of therapy (NCT01002547)
Timeframe: Month 18

Interventionmg/dl (Mean)
Placebo-12
Vitamin E0
Pioglitazone + Vitamin E-4

[back to top]

Fasting Plasma Glucose

Change from baseline after 18 months of therapy (NCT01002547)
Timeframe: Month 18

Interventionmg/dl (Mean)
Placebo6
Vitamin E-3
Pioglitazone + Vitamin E-16

[back to top]

Absolute Change From Baseline in Plasma Gamma-tocopherol (Vitamin E) at Day 7 From Day 0.

Plasma measurements of gamma-tocopherol was assessed in response to smoking cessation and in combination with gamma-tocopherol (vitamin E) supplementation. (NCT01314443)
Timeframe: Day 0 and 7 of intervention

InterventionmicroM (Mean)
Dietary Supplement + Smoking Cessation7.30
Placebo + Smoking Cessation-0.10
Dietary Supplement + Nicotine Replacement Therapy7.28
Placebo + Nicotine Replacement Therapy-0.24

[back to top]

Absolute Change From Baseline in Plasma Malondialdehyde at Day 7 From Day 0.

Plasma measurements of malondialdehyde, a marker of lipid peroxidation was assessed in response to smoking cessation and in combination with gamma-tocopherol (vitamin E) supplementation (NCT01314443)
Timeframe: Day 0 and 7 of intervention

InterventionmicroM (Mean)
Dietary Supplement + Smoking Cessation-0.08
Placebo + Smoking Cessation-0.06
Dietary Supplement + Nicotine Replacement Therapy-0.04
Placebo + Nicotine Replacement Therapy-0.07

[back to top]

Absolute Change in Brachial Artery Flow-mediated Dilation at Day 7 From Day 0

Flow-mediated dilation (FMD) of the brachial artery is measured to assess vascular endothelial function. FMD is obtained by monitoring change in vessel diameter before and after brachial artery occlusion with a blood pressure cuff. The unit of FMD is % and is calculated using the following equation: FMD = [(peak dilation at post occlusion - vessel diameter at preocclusion)/vessel diameter at preocclusion]*100. (NCT01314443)
Timeframe: Day 0 and 7 of intervention

Intervention% of preocclusion diameter (Mean)
Dietary Supplement + Smoking Cessation4.08
Placebo + Smoking Cessation2.77
Dietary Supplement + Nicotine Replacement Therapy2.97
Placebo + Nicotine Replacement Therapy2.66

[back to top]

Biochemical: Number of Patients With Normal Transaminases at End of Treatment.

Biochemical response defined as number of patients with normal transaminases AST <=32 or ALT <=35 U/L at end of treatment. (NCT01792115)
Timeframe: 24 weeks

InterventionParticipants (Count of Participants)
Vit E 200 IU/d6
Vitamin E 4006
Vitamin E 8006

[back to top]

Absolute Change in GGT

Change in GGT by week 24 (U/L) (NCT01792115)
Timeframe: Baseline and 24 weeks

Interventionu/l (Mean)
Vit E 200 IU/d-6.1
Vitamin E 400-22.8
Vitamin E 800-11

[back to top]

Absolute Change in AST

Absolute Change in AST [u/l] by week 24 (NCT01792115)
Timeframe: Baseline and 24 weeks

Interventionu/l (Mean)
Vit E 200 IU/d-5.6
Vitamin E 400-1.8
Vitamin E 800-10.6

[back to top]

Absolute Change in ALT

Absolute Change in ALT [u/l] by week 24 (NCT01792115)
Timeframe: Baseline and 24 weeks

Interventionu/l (Mean)
Vit E 200 IU/d-8
Vitamin E 400-8.3
Vitamin E 800-22

[back to top]

Percent Change in ALT

Percent change in ALT by week 24 (NCT01792115)
Timeframe: Baseline and 24 weeks

Interventionpercent (Mean)
Vit E 200 IU/d-0.17
Vitamin E 400-0.19
Vitamin E 800-0.35

[back to top]

Physiological: Absolute Change in Liver Fat

Physiological response defined as absolute change in liver fat measured by 1H-MRS (NCT01792115)
Timeframe: Baseline and 24 weeks

Interventionpercent liver fat (Mean)
Vit E 200 IU/d-1.9
Vitamin E 400-7.6
Vitamin E 800-0.6

[back to top]

Percent Change in Liver Fat

Percent change in liver fat by week 24 (NCT01792115)
Timeframe: Baseline and 24 weeks

Interventionpercent of percent liver fat (Mean)
Vit E 200 IU/d0.33
Vitamin E 400-0.42
Vitamin E 800-0.10

[back to top]

Percent Change in AST

Percent change in AST by week 24 (NCT01792115)
Timeframe: Baseline and 24 weeks

Interventionpercent (Mean)
Vit E 200 IU/d-0.15
Vitamin E 400-0.07
Vitamin E 800-0.24

[back to top]

Mean Number of Days in ICU.

the mean number of days each subject was in the ICU in each arm (NCT01897792)
Timeframe: from enrollment up to 60 days post enrollment

Interventiondays (Mean)
Vitamins C and E15
0.9% Saline and Sugar Pill11

[back to top]

Mean Number of Hospital Stay Days.

The mean number of days subjects were in the hospital in each arm of the study (NCT01897792)
Timeframe: from enrollment up to 60 days post enrollment

Interventiondays (Mean)
Vitamins C and E18.3
0.9% Saline and Sugar Pill18.2

[back to top]

Mean Number of Ventilator-free Days for Subjects

The mean number of ventilator free days (not on ventilator) for subjects in each arm (NCT01897792)
Timeframe: from enrollment up to 60 days post enrollment

Interventiondays (Mean)
Vitamins C and E12
0.9% Saline and Sugar Pill6.2

[back to top]

Number of Participants With Coagulation Abnormalities

Coagulation parameters are evaluated using standard functional tests (prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen and platelet count)and point of care functional analysis using thromboelastogram (TEG-ROTEM). A blood sample is collected upon arrival in the emergency department at 0 hours only and analyzed for markers of activation of coagulation, inflammation, and levels of vitamin C/E. (NCT01897792)
Timeframe: From enrollment up to 3 days

Interventionparticipants (Number)
Vitamins C and E2
0.9% Saline and Sugar Pill1

[back to top]

Number of Protocol Violations Per Arm.

The number of times that there was a deviation or violation from how the protocol was to be implemented. (NCT01897792)
Timeframe: from enrollment up to 60 days post enrollment

Interventionprotocol deviations (Number)
Vitamin C and E Participants -1
0.9% Saline and Sugar Pill Participants - Protocol Violations0

[back to top]

Number of Subjects Surviving to Day 28

Number of subjects that survived to day 28 after enrollment (NCT01897792)
Timeframe: from enrollment up to 28 days post enrollment

Interventionparticipants (Number)
Vitamins C and E6
0.9% Saline and Sugar Pill5

[back to top]

Number of Subjects With 60-day Survival

Number of subjects in each arm that survived to day 60 (NCT01897792)
Timeframe: from enrollment up to 60 days post enrollment

Interventionparticipants (Number)
Vitamins C and E6
0.9% Saline and Sugar Pill5

[back to top]

Number of Subjects With Organ Injury

Any injury to internal organs (thoracic, abdominal or cranial cavity) (NCT01897792)
Timeframe: From enrollment to 3 days

Interventionparticipants (Number)
Vitamins C and E0
0.9% Saline and Sugar Pill0

[back to top]

Number of Subjects With Ventilator-associated Pneumonia.

Number of subjects diagnosed with pneumonia and requiring ventilator support. (NCT01897792)
Timeframe: From enrollment to 3 days

Interventionparticipants (Number)
Vitamins C and E4
0.9% Saline and Sugar Pill2

[back to top]

Number of Total Blood Product Transfusions

the number of blood product transfusions for all subjects in each group over the course of 3 days. (NCT01897792)
Timeframe: From enrollment to 3 days

Interventionblood transfusions (Number)
Vitamins C and E11
0.9% Saline and Sugar Pill5

[back to top]

Mucociliary Clearance as Affected by Gamma Tocopherol

On day 11 of treatment (approximately 6 hours after the daily dose) with placebo or gamma tocopherol, a whole lung region of interest (ROI) bordering the right lung was used to estimate (by computer analysis) whole lung retention of inhaled radiolabeled particles. This was performed by measuring the labeled particle counts over a 2 hour period and determining the fraction of initial particle counts remaining. From this data, we determined the percentage of labeled particles cleared from the lung during the 2 hour observation period. (NCT02104505)
Timeframe: after 11 days of gamma tocopherol or placebo treatment

Intervention% of labeled particles cleared from lung (Mean)
Gamma Tocopherol21.4
Placebo21.4

[back to top]

Chronic Eosinophilic Airway Inflammation as Affected by Gamma Tocopherol

The sputum eosinophils were measured at baseline (immediately prior to dosing) and again after 14 days of treatment (approximately 8 hours after the final dose) with placebo or gamma tocopherol. The outcome is to compare sputum eosinophils per mg before and after gamma tocopherol treatment. (NCT02104505)
Timeframe: after 14 days of gamma tocopherol or placebo treatment

Interventioneosinophils per mg sputum (Mean)
Gamma Tocopherol2.6
Placebo9.5

[back to top]

Comparison of Change in Sputum Percent Neutrophils (PMN)s Following Inhaled Clinical Center Reference Endotoxin (CCRE) Challenge as Affected by Gamma Tocopherol

In asthmatic individuals, exposure to CCRE is expected to increase PMNs in the sputum. The sputum PMNs were measured at baseline (immediately prior to dosing) and again on day 14 of treatment (approximately 8 hours after the final dose) with placebo or gamma tocopherol. The outcome is to compare the change in PMNs from baseline to post treatment after exposure to CCRE (NCT02104505)
Timeframe: after 14 days of gamma tocopherol or placebo treatment

Interventionchange in percentage of PMNs in sputum (Mean)
Gamma Tocopherol11.7
Placebo20.1

[back to top]

Mucociliary Clearance (MCC) Associated With CCRE Challenge as Affected by Gamma Tocopherol

On day 14 of treatment (approximately 6 hours after the final dose) with placebo or gamma tocopherol, a whole lung region of interest (ROI) bordering the right lung was used to estimate (by computer analysis) whole lung retention of inhaled radiolabeled particles. This was performed by measuring the labeled particle counts over a 2 hour period and determining the fraction of initial particle counts remaining. From this data, we determined the percentage of labeled particles cleared from the lung during the 2 hour observation period. (NCT02104505)
Timeframe: after 14 days of gamma tocopherol or placebo treatment

Intervention% of labeled particles cleared from lung (Mean)
Gamma Tocopherol20.2
Placebo16.3

[back to top]

Clinical Symptoms Evaluation, Measured Using the LENT-SOMA Scale

"Evaluation of symptoms improvement using the LENT-SOMA scale (Late Effect Normal Tissue Task Force / Subjective, Objective, Management, Analytic scale).~To examine the LENT/SOMA scale prospectively using interviews and questionnaires~Assessments were made from baseline to 1, 3, 6 and 9 months of starting treatments. The acceptability and feasibility of using the scales was examined using compliance in completion of the questionnaires.~Maximum score: 36 Minimum score: 0~Questionnaires have been completed for 24 patients after treatment. Higher values represents worse outcome.~Scale categories:~Subjective: pain, nutritional problems, difficulty in mouth openning. Objective: bone exposure, trismus, Management: analgesic treatment, oral treatment, nutrition. Analytic: radiological findings." (NCT02368457)
Timeframe: From baseline to 1,3, 6, 9 months of starting treatment

,
Interventionunits on a scale (Mean)
1 month of starting treatment3 month of starting treatment6 month of starting treatment9 month of starting treatment
CONTROL15.515.515.515.5
Pentoxifylline and Tocopherol14.5141413.3

[back to top]

Bone and/or Tissue Healing as Measured With the Classification of ORN Stages, Area of Bone Exposed (mm2) and Radiological Findings (OPG).

"Clinical healing assessment as measured with the classification of ORN stages, area of bone exposed (mm2) and radiological findings (OPG).~Intraoral bone exposure is measured in mm2." (NCT02368457)
Timeframe: From baseline to 1, 3, 6, and 9 months of starting treatment

,
Interventionmm2 (Mean)
1 month of starting treatment3 month of starting treatment6 month of starting treatment9 month of starting treatment
Control Group15151515
Pentoxifylline and Tocopherol141311.510

[back to top]

Change in Sputum IL-8 From Baseline Following Ozone Exposure

Participants provide induced sputum samples before and 6 hours after Ozone exposure for measurements of inflammatory cytokines. The analysis will determine if gamma tocopherol pre-treatment reduces ozone-induced sputum inflammatory cytokine production compared to placebo pre-treatment. (NCT02911688)
Timeframe: baseline and 6 hours post ozone exposure

Interventionpicograms per milliliter (Mean)
Gamma Tocopherol-341.1
Placebo406.8

[back to top]

Change in Sputum IL-6 From Baseline Following Ozone Exposure

Participants provide induced sputum samples before and 6 hours after Ozone exposure for measurements of inflammatory cytokines. The analysis will determine if gamma tocopherol pre-treatment reduces ozone-induced sputum inflammatory cytokine production compared to placebo pre-treatment. (NCT02911688)
Timeframe: baseline and 6 hours post ozone exposure

Interventionpicograms per milliliter (Mean)
Gamma Tocopherol58.0
Placebo44.3

[back to top]

Change in Central Lung Clearance of Technetium Sulfur Colloid Particles (0-30 Minutes) From Baseline Following Ozone Exposure

Central lung clearance (0-30 minutes) was measured using gamma scintigraphy and represented as mean average 30 minute clearance of inhaled technetium (99mTc) sulfur colloid particles from the large bronchial airways. (NCT02911688)
Timeframe: baseline and 1 hour after exiting ozone chamber

Intervention% clearance (Mean)
Gamma Tocopherol-0.2
Placebo-4.3

[back to top]

Change From Baseline in Sputum Percent Neutrophils (%PMN) Following Ozone Exposure

Participants provide induced sputum samples before and 6 hours after Ozone exposure for measurements of inflammatory cells. The analysis will determine if gamma tocopherol pre-treatment reduces ozone-induced sputum percent neutrophils compared to placebo pre-treatment. (NCT02911688)
Timeframe: baseline and 6 hours post-ozone exposure

Interventionpercent neutrophils (Mean)
Gamma Tocopherol (N=7)34.1
Placebo (N=7)36.5

[back to top]

Change in Whole Lung Clearance of Technetium Sulfur Colloid Particles (0-120 Minutes) From Baseline Following Ozone Exposure

Whole lung clearance was measured using gamma scintigraphy and represented as mean average 120 minute clearance of inhaled technetium (99mTc) sulfur colloid particles in order to estimate the rate of airway mucociliary clearance. (NCT02911688)
Timeframe: baseline and 1 hour after exiting ozone chamber

Intervention% clearance (Mean)
Gamma Tocopherol2
Placebo0

[back to top]

Change in Sputum Tumor Necrosis Factor (TNF)-Alpha From Baseline Following Ozone Exposure

Participants provide induced sputum samples before and 6 hours after Ozone exposure for measurements of inflammatory cytokines. The analysis will determine if gamma tocopherol pre-treatment reduces ozone-induced sputum inflammatory cytokine production compared to placebo pre-treatment. (NCT02911688)
Timeframe: baseline and 6 hours post ozone exposure

Interventionpicograms per milliliter (Mean)
Gamma Tocopherol-61.1
Placebo-301.4

[back to top]

Change in Sputum Percent Eosinophils From Baseline Following Ozone Exposure

The investigators assessed induced sputum cellularity at baseline and 6 hours after ozone exposure to determine if treatment with gamma tocopherol/placebo impacts ozone-induced sputum eosinophilia. (NCT02911688)
Timeframe: baseline and 6 hours post-ozone exposure

Interventionpercent eosinophils (Mean)
Gamma Tocopherol (N=7)0.8
Placebo (N=7)-1.1

[back to top]

Change in Sputum Interleukin (IL)-1b From Baseline Following Ozone Exposure

Participants provide induced sputum samples before and 6 hours after Ozone exposure for measurements of inflammatory cytokines. The analysis will determine if gamma tocopherol pre-treatment reduces ozone-induced sputum inflammatory cytokine production compared to placebo pre-treatment. (NCT02911688)
Timeframe: baseline and 6 hours post ozone exposure

Interventionpicograms per milliliter (Mean)
Gamma Tocopherol-9.7
Placebo176

[back to top]

Delta-plasma Ammonia Concentration

change in delta-plasma ammonia concentration (plasma ammonia at 60 minutes - fasting plasma ammonia during oral protein tolerance test) following Vitamin E supplementation (2 weeks [visit 2] - baseline [visit 1]) (NCT03797222)
Timeframe: 2 weeks

Interventionmicromolar (Mean)
Vitamin E Supplementation-3.4

[back to top]

Delta-plasma Glucose Concentration

change in delta-glucose concentration (fasting plasma glucose - nadir plasma glucose during oral protein tolerance test) following Vitamin E supplementation (2 weeks [visit 2] - baseline [visit 1]) (NCT03797222)
Timeframe: 2 weeks

Interventionmg/dL (Mean)
Vitamin E Supplementation1.1

[back to top]

Delta-plasma Insulin Concentration

change in delta-plasma insulin concentration (peak plasma insulin - fasting plasma insulin during oral protein tolerance test) following Vitamin E supplementation (2 weeks [visit 2] - baseline [visit 1]) (NCT03797222)
Timeframe: 2 weeks

InterventionuIU/mL (Mean)
Vitamin E Supplementation-5.2

[back to top]

Fasting Plasma Ammonia Concentration

change in fasting plasma ammonia concentration following Vitamin E supplementation (2 weeks [visit 2] - baseline [visit 1]) (NCT03797222)
Timeframe: 2 weeks

Interventionmicromolar (Mean)
Vitamin E Supplementation1.0

[back to top]

Fasting Plasma Glucose Concentration

change in fasting plasma glucose concentration following Vitamin E supplementation (2 weeks [visit 2] - baseline [visit 1]) (NCT03797222)
Timeframe: 2 weeks

Interventionmg/dL (Mean)
Vitamin E Supplementation-0.3

[back to top]

Hypoglycemia Frequency

change in frequency of hypoglycemia (plasma glucose <70 mg/dL) detected on home glucose meter following Vitamin E supplementation (2 weeks [visit 2] - baseline [visit 1]) (NCT03797222)
Timeframe: 2 weeks

InterventionHypoglycemia events (Mean)
Vitamin E Supplementation0.6

[back to top]

Nadir Plasma Glucose Concentration

change in nadir plasma glucose concentration during oral protein tolerance test following Vitamin E supplementation (2 weeks [visit 2] - baseline [visit 1]) (NCT03797222)
Timeframe: 2 weeks

Interventionmg/dL (Mean)
Vitamin E Supplementation0.01

[back to top]

Peak Plasma Insulin Concentration

change in peak plasma insulin concentration during oral protein tolerance test following Vitamin E supplementation (2 weeks [visit 2] - baseline [visit 1]) (NCT03797222)
Timeframe: 2 weeks

InterventionuIU/mL (Mean)
Vitamin E Supplementation-6.3

[back to top]

Plasma Alpha-tocopherol Concentration

change in fasting plasma alpha-tocopherol concentration following Vitamin E supplementation (2 weeks [visit 2] - baseline [visit 1]) (NCT03797222)
Timeframe: 2 weeks

Interventionmicromolar (Mean)
Vitamin E Supplementation18.6

[back to top]

Tolerability of Vitamin E Based on Responses to a Subject/Parent-reported Symptom Questionnaire After Vitamin E Supplementation Compared to Baseline

"The following symptoms will be scored as either none (did not occur)=0, mild (minimal symptoms, no treatment needed)=1, moderate (symptoms requiring treatment at home or as an outpatient=2, or severe (symptoms requiring hospitalization or emergency room visit, or life-threatening or potentially life-threatening symptoms)=4:~Seizure, Headache, Vision change/blurred vision, Weakness, Fatigue, Nausea, Vomiting, Diarrhea, Stomach pain, Constipation, Bruising, Bleeding, Rash, Itching, Other~Symptom scores will be summed to yield a Tolerability Questionnaire Score for each participant. The Tolerability Questionnaire Score has a minimum score of 0 (symptoms did not occur) and a maximum score of 60 (all of the measured symptoms occurred, each with severe designation).~The number (count) of participants with an increase in Tolerability Questionnaire Score from baseline to 2 weeks (following Vitamin E supplementation) will be reported." (NCT03797222)
Timeframe: 2 weeks

InterventionParticipants (Count of Participants)
Vitamin E Supplementation2

[back to top]

Fasting Plasma Insulin Concentration

change in fasting plasma insulin concentration following Vitamin E supplementation (2 weeks [visit 2] - baseline [visit 1]) (NCT03797222)
Timeframe: 2 weeks

InterventionuIU/mL (Mean)
Vitamin E Supplementation-2.4

[back to top]

Choosing Other Erectile Dysfunction (ED) Treatments After Pentoxifylline, Atorvastatin and Vitamin E (PAVE)

To report the rate of choosing other ED treatments after PAVE. (NCT03830164)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
Cohort 11
Cohort 20
Cohort 30

[back to top]

Change in International Index of Erectile Function (IIEF) Scores

To estimate the proportion of participants who achieve a clinically significant improvement in erectile dysfunction (ED) when treated with a combination of Atorvastatin or participant's currently prescribed statin, Vitamin E, and Pentoxifylline (PAVE) (NCT03830164)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Cohort 10
Cohort 20
Cohort 30

[back to top]

Number of Participants With Incidence of Adverse Events (AEs)

The safety profile of the pentoxifylline, atorvastatin and vitamin E (PAVE) combination will be reported for each cohort, with adverse events summarized by grade and time to onset to first grade 3 adverse event. (NCT03830164)
Timeframe: Up to 12 months

,,
InterventionParticipants (Count of Participants)
Serious Adverse EventAdverse Event
Cohort 100
Cohort 202
Cohort 300

[back to top]

Number of Subjects With an Improvement in Liver Fibrosis Greater Than or Equal to One Stage and no Worsening of NASH in LPCN 1144 Treated Subjects Compared to Placebo.

These data are based on the NASH-CRN histology scoring system. The range of scores are as follows (with higher scores equating to a more pathological feature): Steatosis 0-3, inflammation 0-3, ballooning 0-2, and fibrosis stage 0-4. Improvement in liver fibrosis was defined as an improvement in fibrosis greater than or equal to one stage using the NASH CRN fibrosis score with no worsening of ballooning, inflammation, or steatosis. (NCT04134091)
Timeframe: Baseline and Week 36

InterventionParticipants (Count of Participants)
Treatment A4
Treatment B2
Treatment C6

[back to top]

Number of Subjects Achieving Resolution of NASH on Overall Histopathological Reading and no Worsening of Liver Fibrosis in LPCN 1144 Treated Subjects Compared to Placebo.

Resolution of NASH is defined as NAS score of 0-1 for inflammation, 0 for ballooning, and any value for steatosis. These data are based on the NASH-CRN histology scoring system. The range of scores are as follows (with higher scores equating to a more pathological feature): Steatosis 0-3, inflammation 0-3, ballooning 0-2, fibrosis state 0-4, and NAS 0-8. No worsening was defined as a score in fibrosis equal to, or lower, than baseline. (NCT04134091)
Timeframe: Baseline and Week 36

InterventionParticipants (Count of Participants)
Treatment A6
Treatment B9
Treatment C0

[back to top]

Number of Participants With Resolution of NASH on Overall Histopathological Reading in LPCN 1144 Treated Subjects Compared to Placebo

Resolution of nonalcoholic steatohepatitis (NASH) is defined as the nonalcoholic fatty liver disease activity score (NAS) score of 0-1 for inflammation, 0 for ballooning, and any value for steatosis. These data are based on the NASH-clinical research network (CRN) histology scoring system. The range of scores are as follows (with higher scores equating to a more pathological feature): Steatosis 0-3, inflammation 0-3, ballooning 0-2, fibrosis state 0-4, and NAS 0-8. (NCT04134091)
Timeframe: Baseline and Week 36

InterventionParticipants (Count of Participants)
Treatment A7
Treatment B9
Treatment C1

[back to top]

Absolute Change in Hepatic Fat Fraction Based on MRI-PDFF Measurements in LPCN 1144 Treated Subjects Compared to Placebo.

The change in magnetic resonance imaging derived proton fat fraction (MRI-PDFF) from baseline to week 12 in LPCN 1144 treated subjects and subjects given placebo. (NCT04134091)
Timeframe: Baseline and Week 12

InterventionPercentage of liver fat (Least Squares Mean)
Treatment A-7.68
Treatment B-9.17
Treatment C-1.54

[back to top]

Mean Changes in Serum Lipid Profile Parameters in LPCN 1144 Treated Subjects Compared to Placebo.

Lipid profile parameters included total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides. (NCT04134091)
Timeframe: Baseline and Week 36

,,
Interventionmg/dL (Least Squares Mean)
Total CholesterolLDLHDLTriglycerides
Treatment A-1.71.8-3.3-11.5
Treatment B7.38.7-2.0-3.9
Treatment C1.1-6.0-0.067.3

[back to top]

Mean Change From Baseline in Liver Enzymes in LPCN 1144 Treated Subjects Compared to Placebo.

Liver enzymes analyzed were aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), and gamma-glutamyltransferase (GGT) (NCT04134091)
Timeframe: Baseline and Week 36

,,
InterventionU/L (Least Squares Mean)
Aspartate transaminase (AST)Alanine transaminase (ALT)Alkaline phosphatase (ALP)Gamma-glutamyltransferase (GGT)
Treatment A-8.0-11.4-6.1-2.9
Treatment B-12.0-22.9-8.5-13.4
Treatment C1.30.60.10.7

[back to top]

Change in the Mean Score of NAS Components at Baseline and After 36 Weeks of Treatment in LPCN 1144 Treated Subjects Compared to Placebo.

These data are based on the NASH-CRN histology scoring system. The range of scores are as follows (with higher scores equating to a more pathological feature): Steatosis 0-3, inflammation 0-3, ballooning 0-2, fibrosis state 0-4, and NAS 0-8. (NCT04134091)
Timeframe: Baseline and Week 36

,,
InterventionNAS score (Least Squares Mean)
Hepatocyte ballooning scoreLobular inflammation scoreSteatosis score
Treatment A-0.7-0.2-0.9
Treatment B-0.9-0.5-1.2
Treatment C-0.2-0.1-0.1

[back to top]

Relative Change in Whole Body Fat Mass

Relative change in whole body fat mass measured by dual-energy absorptiometry (DXA) in LPCN 1144 treated subjects compared to Placebo. Data were last observation carried forward. (NCT04134091)
Timeframe: Baseline and week 36

InterventionPercentage change (Least Squares Mean)
Treatment A-3.68
Treatment B-7.33
Treatment C1.78

[back to top]

Relative Change in MRI-PDFF Measurements in LPCN 1144 Treated Subjects Compared to Placebo.

Requirement for inclusion in analysis was having a baseline hepatic fat fraction ≥ 5% based on MRI-PDFF. (NCT04134091)
Timeframe: Baseline and week 12

InterventionPercentage change (Least Squares Mean)
Treatment A-39.94
Treatment B-46.84
Treatment C-9.34

[back to top]

Relative Change in Appendicular Lean Muscle Mass

Relative change in appendicular lean muscle mass measured by dual-energy absorptiometry (DXA) in LPCN 1144 treated subjects compared to Placebo. Data were last observation carried forward. (NCT04134091)
Timeframe: Baseline and 36 weeks

InterventionPercentage change (Least Squares Mean)
Treatment A2.75
Treatment B1.90
Treatment C-1.42

[back to top]

Number of Subjects With Improvement in NASH Evaluated by Paired Biopsies Analysis and no Worsening of Liver Fibrosis in LPCN 1144 Treated Subjects Compared to Placebo.

Paired biopsies are randomly assigned A or B and are scored by a blinded pathologist as better, worse or same for change in fibrosis, steatosis, inflammation, and ballooning. Improvement in NASH requires no worsening of fibrosis, an improvement in ballooning or inflammation, and no worsening of ballooning or inflammation. Assessment of better or same is considered as no worsening. (NCT04134091)
Timeframe: Baseline and week 36

InterventionParticipants (Count of Participants)
Treatment A9
Treatment B8
Treatment C2

[back to top]

Number of Subjects With Improvement in Fibrosis Evaluated Via FibroNest Scores

Improvement in Fibrosis is defined as improvement in parenchymal tissue normalized phenotypic fibrosis composite value compared to baseline. FibroNest is an image analysis system for the assessment of the severity and progression of fibrosis in NASH, produced by PharmaNest LLC. (NCT04134091)
Timeframe: Baseline and week 36

InterventionParticipants (Count of Participants)
Treatment A12
Treatment B6
Treatment C5

[back to top]

Number of Subjects With Improvement in Fibrosis Evaluated by Paired Biopsies Analysis and no Worsening of NASH in LPCN 1144 Treated Subjects Compared to Placebo

Paired biopsies are randomly assigned A or B and are scored by a blinded pathologist as better, worse or same for change in fibrosis, steatosis, inflammation, and ballooning. Improvement in fibrosis requires a better score in fibrosis and no worsening of ballooning or inflammation. Assessment of better or same is considered as no worsening. (NCT04134091)
Timeframe: Baseline to week 36

InterventionParticipants (Count of Participants)
Treatment A6
Treatment B8
Treatment C3

[back to top]

Change in Fibrosis-4 (FIB-4) Score

The formula for FIB-4 is: Age ([yr] x AST [U/L]) / ((PLT [10(9)/L]) x (ALT [U/L])(1/2)). A value of FIB-4 below 1.30 is considered as low risk for advanced fibrosis; a value of FIB-4 over 2.67 is considered as high risk for advanced fibrosis (NCT04198805)
Timeframe: Baseline to 6 months

Interventionunits on a scale (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)-0.1
Vitamin E (1000 mg)-0.2
DHA EE (1.89 g)-0.1
Placebo-0.0

[back to top]

Change in Hepatic Fat Fraction [%] Between DHA EE vs Placebo Arm

Change in liver fat content relative to baseline between DHA EE vs placebo arm. This will be measured by MRI-PDFF at baseline and after 6 months of intervention (value at 6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

InterventionPercentage of liver fat (Mean)
DHA EE (1.89 g)2.2
Placebo-8.2

[back to top]

Change in Hepatic Fat Fraction [%] Between of Vitamin E and DHA EE vs Placebo

A change in liver fat content relative to baseline between Vitamin E and DHA EE vs placebo. This will be measured by MRI-PDFF at baseline and after 6 months of intervention (value at 6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

InterventionPercentage of liver fat (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)-6.8
Placebo-8.2

[back to top]

Change in Hepatic Fat Fraction [%] Between Vitamin E vs Placebo Arm

Change in liver fat content relative to baseline between Vitamin E vs placebo arm. This will be measured by MRI-PDFF at baseline and after 6 months of intervention (value at 6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

InterventionPercentage of liver fat (Mean)
Vitamin E (1000 mg)-10.4
Placebo-8.2

[back to top]

Liver Enzymes Alkaline Phosphatase in the DHA EE and /or Vitamin E Intervention Over a 6 Month Period.

Evaluation of baseline and 6-month liver enzymes: Alkaline Phosphatase in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

InterventionU/L (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)-4.1
Vitamin E (1000 mg)-0.4
DHA EE (1.89 g)1.1
Placebo2.5

[back to top] [back to top]

Change in Plasma Vitamin E Concentration

Evaluation of baseline and 6-month plasma Vitamin E concentration in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

Interventionng/mL (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)6972
Vitamin E (1000 mg)9949
DHA EE (1.89 g)480.9
Placebo148.0

[back to top]

Change in Plasma DHA EE Concentration

Evaluation of baseline and 6-month plasma DHA EE concentration in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

Interventionug/mL (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)41.6
Vitamin E (1000 mg)0.6
DHA EE (1.89 g)52.8
Placebo-2.6

[back to top]

Change in Liver Enzymes Bilirubin in the DHA EE and /or Vitamin E Intervention Over a 6 Month Period.

Evaluation of baseline and 6-month liver enzymes: Bilirubin in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

Interventionmg/dL (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)0.1
Vitamin E (1000 mg)-0.0
DHA EE (1.89 g)-0.0
Placebo0.1

[back to top]

Change in Liver Enzymes (AST) in the DHA EE and /or Vitamin E Intervention Over a 6 Month Period.

Evaluation of baseline and 6-month liver enzymes: aspartate aminotransferase (AST) in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

InterventionU/L (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)-1.4
Vitamin E (1000 mg)-6.4
DHA EE (1.89 g)2.9
Placebo-2.8

[back to top]

Change in Liver Enzymes (ALT) in the DHA EE and /or Vitamin E Intervention Over a 6 Month Period.

Evaluation of baseline and 6-month liver enzymes: alanine transaminase (ALT) in the DHA EE and /or Vitamin E intervention over a 6 month period value at (6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

InterventionU/L (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)-4.6
Vitamin E (1000 mg)-16.7
DHA EE (1.89 g)7.0
Placebo-6.8

[back to top]

Change in Lipid Profile (Triglycerides)

Evaluation of baseline and 6-month lipid profile (TGs)in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

Interventionmg/dL (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)-23.1
Vitamin E (1000 mg)2.0
DHA EE (1.89 g)-6.6
Placebo-21.4

[back to top]

Change in Dietary Intake Levels of Long-chain Polyunsaturated Fatty Acids (LC-PUFA ) (i.e. DHA and EPA) as Measured by the Food Frequency Questionnaire (FFQ)

Evaluation of baseline and 6-month dietary intake levels of LC-PUFA (i.e. DHA and EPA) as measured by the Food Frequency Questionnaire (FFQ)in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

,,,
Interventionmg per day (Mean)
FFQ DHAFFQ EPA
DHA EE (1.89 g)-0.7-0.6
DHA EE (1.89 g) and Vitamin E (1000 mg)2.30.7
Placebo-1.6-0.8
Vitamin E (1000 mg)4.42.4

[back to top]

Change in Lipid Profile (Oxidized LDL)

Evaluation of baseline and 6-month lipid profile (oxidized LDL) in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

InterventionU/L (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)4.1
Vitamin E (1000 mg)5.3
DHA EE (1.89 g)4.6
Placebo0.5

[back to top]

Change in Lipid Profile (Low Density Lipoprotein (LDL-C))

Evaluation of baseline and 6-month lipid profile (low density lipoprotein (LDL-C))in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

Interventionmg/dL (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)9.9
Vitamin E (1000 mg)2.1
DHA EE (1.89 g)19.4
Placebo5.1

[back to top]

Change in Lipid Profile (HDL-C)

Evaluation of baseline and 6-month lipid profile (HDL-C) in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

Interventionmg/dL (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)1.7
Vitamin E (1000 mg)0.0
DHA EE (1.89 g)2.4
Placebo0.5

[back to top]

Change in Insulin Levels to Determine Insulin Resistance

(NCT04198805)
Timeframe: Baseline to 6 months

InterventionulU/mL (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)4.7
Vitamin E (1000 mg)-5.7
DHA EE (1.89 g)9.9
Placebo4.3

[back to top]

Change in Inflammatory Markers (TNFα)

Evaluation of baseline and 6-month inflammatory markers (TNFα) in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

Interventionpg/mL (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)-1.3
Vitamin E (1000 mg)-0.2
DHA EE (1.89 g)-0.3
Placebo-0.5

[back to top]

Change in Inflammatory Markers (IL-1β)

Evaluation of baseline and 6-month inflammatory markers (IL-1β) in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

Interventionpg/mL (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)0.0
Vitamin E (1000 mg)-0.1
DHA EE (1.89 g)0.2
Placebo-0.4

[back to top]

Change After 6 Months of DHA EE and /or Vitamin E Intervention in the Anthropometric Measure, Bodyweight.

Evaluation of baseline and 6-month measurements of body weight in the DHA EE and /or Vitamin E intervention over a 6 month period. (NCT04198805)
Timeframe: Baseline to 6 months

Interventionkilogram (kg) (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)0.4
Vitamin E (1000 mg)0.5
DHA EE (1.89 g)0.0
Placebo-0.0

[back to top]

Change After 6 Months of DHA EE and/ or Vitamin E Intervention in the Anthropometric Measure, Body Mass Index (BMI)

Evaluation of baseline and 6-month measurements of body mass index (BMI) in the DHA EE and /or Vitamin E intervention over a 6 month period. (NCT04198805)
Timeframe: Baseline to 6 months

Interventionkg/m^2 (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)0.1
Vitamin E (1000 mg)0.2
DHA EE (1.89 g)-0.0
Placebo-0.0

[back to top]

Change After 6 Months of DHA EE and/ or Vitamin E Intervention in the Anthropometric Measure, Waist Circumference.

Evaluation of baseline and 6 month measurements of waist circumference in the DHA EE and /or Vitamin E intervention over a 6 month period. (NCT04198805)
Timeframe: Baseline to 6 months

Interventioncentimeters (cm) (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)0.8
Vitamin E (1000 mg)-0.5
DHA EE (1.89 g)-0.2
Placebo0.8

[back to top]

Change After 6 Months of DHA EE and/ or Vitamin E Intervention in the Anthropometric Measure, Waist-to-hip Ratio .

Evaluation of baseline and 6-month measurements of waist-to-hip ratio (the circumference of the waist divided by the circumference of the hips) in the DHA EE and /or Vitamin E intervention over a 6 month period. (NCT04198805)
Timeframe: Baseline to 6 months

Interventionratio (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)0.0
Vitamin E (1000 mg)-0.0
DHA EE (1.89 g)0.0
Placebo-0.0

[back to top]

Change in Inflammatory Markers (Cytokeratin 18 (CK-18))

Evaluation of baseline and 6-month inflammatory markers (cytokeratin 18) in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline). (NCT04198805)
Timeframe: Baseline to 6 months

InterventionU/L (Mean)
DHA EE (1.89 g) and Vitamin E (1000 mg)-17.7
Vitamin E (1000 mg)-26.8
DHA EE (1.89 g)37.3
Placebo61

[back to top]